The biology of ergothioneine, an antioxidant nutraceutical

Irina Borodina1, Louise C. Kenny2, Cathal M. McCarthy3,4, Kalaivani Paramasivan1, Etheresia Pretorius5, Timothy J. Roberts5,6, Steven A. van der Hoek1 and Douglas B. Kell1,5,6

1The Novo Nordisk Foundation Center for Biosustainability, Building 220, Chemitorvet 200, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
2Department of Women’s and Children’s Health, Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool L8 7SS, UK
3Irish Centre for Fetal and Neonatal Translational Research (INFANT), Cork University Maternity Hospital, Cork, Republic of Ireland
4Department of Pharmacology and Therapeutics, Western Gateway Building, University College Cork, Cork, Republic of Ireland
5Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, Private Bag X1 Matieland, 7602, South Africa
6Department of Biochemistry, Institute of Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown Street, Liverpool L69 7ZB, UK

Abstract

Ergothioneine (ERG) is an unusual thio-histidine betaine amino acid that has potent antioxidant activities. It is synthesised by a variety of microbes, especially fungi (including in mushroom fruiting bodies) and actinobacteria, but is not synthesised by plants and animals who acquire it via the soil and their diet, respectively. Animals have evolved a highly selective transporter for it, known as solute carrier family 22, member 4 (SLC22A4) in humans, signifying its importance, and ERG may even have the status of a vitamin. ERG accumulates differentially in various tissues, according to their expression of SLC22A4, favouring those such as erythrocytes that may be subject to oxidative stress. Mushroom or ERG consumption seems to provide significant prevention against oxidative stress in a large variety of systems. ERG seems to have strong cytoprotective status, and its concentration is lowered in a number of chronic inflammatory diseases. It has been passed as safe by regulatory agencies, and may have value as a nutraceutical and antioxidant more generally.

Key words: Ergothioneine: SLC22A4: Oxidative stress: Cytoprotectants: Nutraceuticals

Introduction

Most of the classical vitamins such as vitamins A, B1, B2, B3, C, D, etc., were discovered by means of the fact that an inadequacy in their supply led to overt forms of deficiency disease such as blindness, beri-beri, pellagra, scurvy, rickets and so on. Consequently, it was easy to establish those food sources that contained such vitamins, since they relieved or prevented the relevant syndromes1,2. It is correspondingly hard, by these means, to detect the presence of a vitamin if it is present in virtually every foodstuff that an individual consumes. Recently, however, L-(+)-ergothioneine, hereafter ergothioneine (ERG), has emerged5–10 as an important nutrient, and indeed possible vitamin5, that has precisely these properties of a very widespread occurrence coupled, commonly, to a functional undersupply.

A related class of nutrient, which has not been demonstrated as necessary or essential for life yet provides health benefits when added at levels greater than a normal diet generally provides, has come to be known as nutraceuticals, a coinage based on an amalgamation of ‘nutrition’ and ‘pharmaceutical’11. Interest in such nutraceuticals, also known as ‘functional foods’, has increased enormously over the last few decades11–22 as our understanding of the important roles of diet in health has improved. However, the enthusiasm for such products has not always been matched by the extent or quality of the evidence for their efficacy20,23–28.

Since ERG classes as a nutraceutical, it seems timely to bring together the extensive but widespread knowledge of its biology so that it may be made more widely available, and that is the purpose of this review.

Discovery and structure

ERG is a somewhat unusual betaine amino acid. It was discovered by Charles Tanret in 1909 while investigating the ergot
The biology of ergothioneine

fungus Claviceps purpurea\(^{(29,80)}\). It is also known as 2-mercaptohistidine trimethylbetaine, and its formal International Union of Pure and Applied Chemistry (IUPAC) name is (25)-3-(2-thioxo-2,3-dihydro-1H-imidazol-4-yl)-2-(trimethylammonio)propanoate. It is an \(L\)-histidine derivative that is \(N\^\alpha,N^\alpha,N^\alpha\)-trimethyl-L-histidine in which the hydrogen at position 2 on the imidazole ring is replaced by a mercapto group. Its structure\(^{(31)}\), and those of some related molecules, is given in Fig. 1, indicating that it is a tautomer in which the hydrogen at position 2 on the imidazole ring is replaced by a mercapto group. Although it is a thiol, and hence an antioxidant\(^{(32,33)}\), the thione tautomer is predominant at that has both a thiol and a thione form. Although it is a thiol, and is known as selenoneine and also has strong antioxidant properties\(^{(45-52)}\), but is not otherwise discussed here.

From a pharmaco-chemical point of view ERG is also unusual, since – using our standard substructure analysis\(^{(53,54)}\) in KNIME\(^{(55)}\) – we note that just two drugs marketed for human consumption (the anti-thyroixine-production drug methimazole, and its pro-drug carbimazole, Fig. 1), and no endogenous genome-encoded metabolites from Recon2\(^{(56)}\) contain the imidazole-2-thione substructure\(^{(57)}\). This said, a good many fungicides do contain the benzimidazole substructure\(^{(58)}\), and a variety of benzothiazoles are used as dyes.

**Biosynthesis and phylogenetic distribution**

A particular feature of ERG is that although it is more or less universally distributed among higher organisms, none of them – as is consistent with the idea that it may in fact be a vitamin requiring exogeneous sources – can in fact biosynthesise it. The chief organisms capable of its synthesis are fungi and certain yeasts\(^{(59,60)}\), though actinobacteria and certain other micro-organisms\(^{(60-66)}\), including the slime mould Physarum polycephalum\(^{(65)}\), cyanobacteria\(^{(67-71)}\) and methylotrophs\(^{(72)}\) are also naturally capable of its production. The related mycothiol is typically ten times more concentrated in actinobacteria than is ERG\(^{(73)}\), and its biosynthetic pathway might provide an antitubercular drug target. Other organisms acquire ERG through transporter-mediated uptake. Thus higher plants contain it but do not biosynthesise it\(^{(74)}\); instead they and other organisms\(^{(68,75)}\) take it up from fungal production in the soil\(^{(76-79)}\), and possibly via actinobacterial\(^{(80)}\) or fungal\(^{(80,83)}\) symbionts. Animals are also considered not to biosynthesise it\(^{(84)}\), and accumulate it using a particular transporter, detailed below, via the plants and animals that they eat. Although not easy, it is possible to raise animals such as pigs on a diet such as casein, sucrose, land, butter and salts that is considered to lack ERG; such animals are said to have undetectable levels of the compound\(^{(84)}\), and rats treated similarly have reproduced\(^{(85,86)}\). However, we do not know the minimum amount and its location that animals need, and these are old experiments that need to be repeated with modern techniques with lower detection limits. Only then might we have a definitive statement as to whether ERG is absolutely required as a true vitamin or not, and if so in what amounts for health. In a similar vein, ERG can be present in cell culture media and cells with organic cation transporter N1 (OCTN1)/solute carrier family 22, member 4 (SLC22A4) can accumulate it\(^{(87)}\), a fact little considered to date in cell culture studies.

To the extent that ERG is a ‘secondary’ metabolite, defined\(^{(88)}\) as a molecule whose synthesis has a relatively restricted distribution in different organisms, the biosynthetic pathways diverge from primary metabolism via the amino acids histidine, cysteine and methionine\(^{(89-94)}\). Thus (Fig. 2), histidine is trimethylated

![Fig. 1. Structures of ergothioneine and related molecules. For a colour figure, see the online version of the paper.](image-url)
using S-adenosyl methionine to form trimethyl histidine, also known as hercynine\(^{(95,96)}\). This reacts oxidatively with cysteine to form hercynylcysteine sulfoxide\(^{(97)}\), which is converted to ERG. In some organisms, hercynine takes a more convoluted route via \(\gamma\)-glutamylhercynylcysteine sulfoxide (Fig. 2)\(^{(94)}\). Table 1 provides references for different organisms. An excellent phylogenetic analysis is given by Jones et al.\(^{(60)}\).

In more recent work, it has been suggested that ERG was probably first biosynthesised by anaerobes using a slightly different route that converts hercynine directly to ERG\(^{(98 – 100)}\), and that was later repurposed.

Three-dimensional structures are known for a number of the relevant enzymes, including mycobacterial EgtB\(^{(101)}\) for example, PDB 4XBE, EgtC\(^{(102)}\) for example, PDB 4ZFJ, EgtT\(^{(103 – 105)}\) for example, PDB 4PIM, and Neurospora crassa early G1 transcript 2 (egt2) which is like egtE\(^{(106)}\) for example, PDB 5UTS.

Very recently, EgtB from Candidatus Chloracidobacterium thermophilum was crystallised\(^{(107)}\), and engineered towards Egt1 activity. Thumbnails are given in Fig. 2. Egt1 from N. crassa is 876 amino acids long\(^{(108)}\), while egtD from Mycobacterium tuberculosis\(^{(109)}\) is just 321 amino acids long; since the N-terminal sequences are well conserved (Fig. 3), this implies an extra C-terminal domain catalysing the production of hercynylcysteine sulfoxide from hercynine.

In addition, enantiopure L-ERG has been synthesised chemically\(^{(76,110 – 112)}\), and by fermentation of genetically engineered micro-organisms (Table 2). Initial efforts in ERG synthesis were carried out in Schizosaccharomyces pombe using egt1 overexpression under an inducible promoter. The N starvation and glucose starvation conditions causing long quiescence led to the maximum ERG production of 1606-3 \(\mu\)M while the wild-type strain produced 0-3 \(\mu\)M\(^{(50)}\). Methylobacterium aquaticum strain 22A was engineered by expressing an additional copy of egtBD genes and by deleting the gene encoding histidine ammonia lyase, which degrades an ERG precursor L-histidine. The resulting strain produced up to 7-0 mg EGT/g dry cell weight and 100 \(\mu\)g EGT/5 ml per 7 d in test-tubes\(^{(113)}\). The filamentous fungus Aspergillus oryzae has also been engineered to produce ERG by expression of egt1 and egt2 genes from N. crassa, resulting in 231 mg ERG per kg of solid media\(^{(114)}\).

Expression of egtBCDE genes from Mycobacterium smegmatis in Escherichia coli and optimisation of medium composition has led to 24 mg/l or 104 \(\mu\)M of secreted ERG\(^{(115)}\). The egtA gene from M. smegmatis was not expressed because E. coli contains a homologous glutamate-cysteine ligase encoded by gsbA and involved in glutathione biosynthesis.

### Table 1. Biosynthesis of ergothioneine in various non-recombinant micro-organisms

| Organism                             | Selected references |
|--------------------------------------|---------------------|
| Aspergillus fumigatus                | (257)               |
| Aspergillus niger                    | (58)                |
| Aureobasidium pullulans              | (113)               |
| Burkholderia pseudomallei            | (565)               |
| Chlorobium limicola                  | (96,100)            |
| Claviceps purpurea                   | (105,566,567)       |
| Lactobacillus casei                  | (568)               |
| Methylobacterium aquaticum           | (72)                |
| Mycobacterium tuberculosis           | (91-93)             |
| Neurospora crassa                    | (89)                |
| Schizosaccharomyces pombe            | (50,569)            |
| Streptomyces coelicolor              | (255)               |

---

**Fig. 2.** The two main pathways of aerobic ergothioneine (ERG) biosynthesis, noting the relevant enzymes and thumbnails of three-dimensional structures where known. SAM, S-adenosyl methionine. For a colour figure, see the online version of the paper.
In a follow-up study, the authors expressed egtA from *M. smegmatis* and it had a positive effect on ERG production. Furthermore, they enhanced cysteine and S-adenosine methionine biosynthesis and obtained 1.3 g/l or ERG in a fed-batch fermentation, achieving currently the highest titre reported for heterologous ERG production.

Recently, we reported the engineering of baker’s yeast *Saccharomyces cerevisiae* for the production of ERG.

### Table 2. Fermentative production of ergothioneine in recombinant micro-organisms

| Organism                   | Genetic modification(s)                                                                 | Titre          | Conditions                                                                 | Reference |
|----------------------------|----------------------------------------------------------------------------------------|----------------|---------------------------------------------------------------------------|-----------|
| *Aspergillus oryzae*       | Expression of *egt1* and *egt2* genes from *Neurospora crassa*                          | 231.0 mg/kg of media | Cultivation on solid, rice-based medium                                     | (114)     |
| *Escherichia coli*         | Expression of *egtBCDDE* genes from *Mycobacterium smegmatis*                          | 24 (extracellular) | Shake flasks. Medium supplemented with yeast extract, His, Met, 20 μM-thiosulfate as sulfur source for L-cysteine synthesis. IPTG for inducing heterologous gene expression | (115)     |
| *Escherichia coli*         | Expression of the following genes: *egtABCDE* from *M. smegmatis*, altered *cysE* gene encoding serine acetyltransferase feed-back resistant to Cys, native *ydeD* gene encoding inner membrane Cys exporter, altered *serA* gene encoding L-serine Feedback inhibition-insensitive mutant of d-3-phosphoglycerate dehydrogenase. Deletion of *metJ* gene encoding transcriptional repressor. | 1.3 g/l (extracellular) | Fed-batch in 3-litre bioreactor, 216 h. Complex medium supplemented with IPTG, ammonium ferric citrate, pyridoxine, Met, His, and thiosulfate | (116)     |
| *Methylobacterium aquaticum* strain 22A | Additional copy of *egtBD* expressed from a plasmid, deletion of histidine ammonia-lyase (*hutH*) gene | 20 mg/l | Test-tubes. Complex medium with methanol | (113)     |
| *Saccharomyces cerevisiae* | 598 (so 18) mg/l, of which 59% was extracellular                                       | 598 mg/l       | Fed-batch fermentation in 1-litre bioreactor, 84 h. Defined medium supplemented with arginine, histidine, methionine and pyridoxine | (570)     |
| *Schizosaccharomyces pombe* | *egt1* overexpression under inducible promoter                                           | 368 mg/l       | N and glucose starvation. Cultivation method not given                     | (50)      |

**Table**: Alignment of *Neurospora crassa* Egt1 and the N-terminal part of *Mycobacterium tuberculosis* EgtD. For a colour figure, see the online version of the paper.

**IPTG**, isopropyl β- d-1-thiogalactopyranoside.

In a follow-up study, the authors expressed egtA from *M. smegmatis* and it had a positive effect on ERG production. Furthermore, they enhanced cysteine and S-adenosine methionine biosynthesis and obtained 1.3 g/l or ERG in a fed-batch fermentation, achieving currently the highest titre reported for heterologous ERG production.

Recently, we reported the engineering of baker’s yeast *Saccharomyces cerevisiae* for the production of ERG.
S. cerevisiae has a generally recognised as safe (GRAS) status and has been exploited for the commercial production of several nutraceutical compounds\(^{118}\); it is thus a highly attractive host for the production of ERG. We have tested sixteen different pathway variants, nine containing only fungal genes, one with bacterial genes from M. smegmatis, and six hybrid pathway variants containing both fungal and bacterial transgenes. The best-performing strain contained egt1 from N. crassa and egt2 from C. purpurea. The composition of the medium was improved using a fractional factorial design. Fed-batch cultivation resulted in 598 (SD 18) mg/l ERG after an 84-h fermentation. Some 60% of the measured ERG was extracellular and the rest accumulated in the cells. Table 2 summarises the various recombinant expression hosts that have been used.

The distribution of solute transporters between tissues in differentiated organisms is particularly heterogeneous\(^{119}\) and it is to be expected that both SLC22A4 and ERG might also be distributed heterogeneously as well. This is indeed the case, their distribution being especially high in tissues that are considered to have the potential for oxidative stress\(^{4,9}\), such as erythrocytes\(^{120-129}\), bone marrow\(^{130}\), liver and kidney\(^{85,131}\), seminal fluid\(^{132,133}\) and the lens and cornea of the eyes\(^{134}\). It may also be accumulated in the CNS\(^{135,136}\).

Finally, here, we note – as with the activity of the ‘master Fe regulator’ hepcidin\(^{137-141}\), that acts chiefly via the ferrous Fe transporter ferroportin – that the action of a transporter in concentrating a substance in one tissue will typically lead to its depletion from another. Consequently, it is necessary to measure all relevant compartments to assess whether a molecule such as ERG, whose distribution is strictly transporter-mediated, is protective against a particular disease/effect or otherwise in a particular place or case.

**SLC22A4: the ergothioneine transporter**

Although this view remains controversial, even hydrophobic molecules do not normally ‘float across’ whatever phospholipid bilayer portion of cells may be untrammelled by proteins. Xenobiotics in particular need to ‘hitchhike’ on protein transporters that have presumably evolved for ‘natural’ substrates but that are capable of their uptake\(^{142-151}\). While transporters seem to have remained somewhat understudied\(^{155}\), those transporters involved in uptake and encoded by the human genome are now catalogued formally as SLC for solute carriers\(^{154,155}\), with efflux transporters mainly being classed as ABC families\(^{156}\).

One solute carrier, previously known as organic cation transporter N1 (OCTN1)\(^{157,158}\), and now known as SLC22A4 (the human version is Uniprot Q9H105), a 551-amino-acid transporter with three glycosylation sites, is of special interest. It had been designated as a transporter of carmine and of the (non-physiological) tetaethylammonium cation. However, in a really groundbreaking paper, Gründemann et al.\(^{159}\) recognised that the rates observed (using radioisotopes) were too small to be physiologically meaningful, and using a method that we would now refer to as ‘untargeted metabolomics’\(^{159-164}\), they incubated two kinds of HEK-293 cells in serum. The first were normal cells, that, as with many transporters\(^{119}\), do not in fact express SLC22A4 at significant levels, while the second had been engineered to overexpress the transporter. They then simply looked for those molecules that were most differentially taken up, a molecule called stachydrine, also known as proline betaine, being the main one observed. Stachydrine is a constituent of citrus juices\(^{165-167}\). Some elementary cheminformatics based on structure similarity searches\(^{57,168}\) indicated that ERG, as a betaine, was indeed similar to stachydrine. Incubating the cells just with ERG showed that it was taken up about 100 times more quickly than was tetaethylammonium, leading to the designation of SLC22A4 as ‘the’ ERG transporter\(^{130}\). Subsequent work\(^{169-172}\) has confirmed and reinforced this view of SLC22A4 and its homologues\(^{173}–^{175}\) as having significant specificity for ERG, and weak activity for various drugs\(^{174-177}\). It is concentrative, coupled in humans to influx of 2 or 3 Na\(^+\) ions per ERG transported\(^{130}\). Interestingly, it is up-regulated chronobiologically just before meal times\(^{175}\). The rat and human orthologues are interchangeable\(^{178}\). Tissue levels of ERG depend on an exogenous supply\(^{179}\), but are then well correlated with the expression levels of SLC22A4\(^{3,180}\). SLC22A4 expresses well even in microbial systems\(^{181}\), and is widely tolerant of amino acid substitutions\(^{182}\). As yet, no other transporter with significant activity for ERG in humans is known, making it a potentially interesting drug target\(^{183,184}\).

**Expression patterns**

SLC22A4 is known to express in the intestinal lumen\(^{185}\), acting to take up ERG, as well as some xenobiotics including pyrrolidine, quinidine and verapamil, and having multiple known but weak inhibitors.

Fig. 4 shows the expression of the transcript for SLC22A4 in fifty-six cell lines using previous data\(^{119}\) taken from the human protein atlas\(^{186}\), indicating a range in expression levels between different cell lines of more than 4000-fold, a number not atypical for human transporters\(^{119}\). Tissue expression data are given in Fig. S4 of O’Hagan et al.\(^{119}\).

The intracellular expression patterns are as yet uncertain, with early claims for a mitochondrial expression\(^{186,187-189}\) being based on very weak and contradictory evidence\(^{3}\). However, while the cellular uptake of ERG does require plasma membrane expression, the latest version of the protein atlas indicates mitochondrial expression as well\(^{191}\). However, as is well known, antibody specificities are rarely either known or absolute\(^{192-199}\). Thus, relying on antibody evidence alone is rather hazardous, and, as mentioned before\(^{38}\), mitochondrial transporters have an SLC25 family designation\(^{199,200}\). Definitive measurements on the uptake or otherwise of ERG into isolated mitochondria, or indeed into other organisms that cannot make it, are eagerly awaited.

**Evolution and phylogenetic distribution of SLC22A4**

Phylogenetic analyses\(^{201,202}\) indicate that homologues of SLC22A4, a relative of the major facilitator superfamily 2, exist only in vertebrate animals, especially mammals, birds and fish, with occasional examples in reptiles (for example, Xenopus spp.).

In practice, it appears that the transporters responsible for the uptake of some 85% of pharmaceutical drugs actually evolved to
take up exogenous natural products. In the case of the cocaine transporter, a simple narrative can serve to explain how a cocaine-mediated ability to outrun a predator such as a sabre-tooth tiger can rather obviously be selected provided the bioactive substance is actually taken up by the host. More generally, the ability to transport exogenous natural products is likely to be selected for when these confer fitness benefits on the host, and this probably underpins the finding that successful, marketed drugs are indeed similar to (mainly ‘secondary’) natural products.

Oxidative stress

Oxidative stress is widespread to the point of ubiquity in chronic, inflammatory diseases, with over fifty papers having the words ‘oxidative’, ‘stress’ and ‘review’ in their titles at PubMed in 2018 alone! It can occur when oxygen tension is low and respiratory chains are over-reduced such that they reduce O2 with one electron to superoxide or two electrons to H2O2, instead of the four that are used during the reduction of dioxygen to water by cytochrome oxidase (Fig. 5). Peroxides are also produced in vitro by various oxidases and peroxidases, such as xanthine oxidase, by reduction of dioxygen (for example, Babior, Cave et al. and Bedard & Krause).

While H2O2 and superoxide are certainly capable of effecting unwanted oxidations, it is the hydroxyl radical that is the key. Thus an important reaction of H2O2 with (free or poorly liganded) Fe(II) is the Fenton reaction, leading to the very reactive and damaging hydroxyl radical (OH•):

\[
\text{Fe(II)} + \text{H}_2\text{O}_2 \rightarrow \text{Fe(III)} + \text{OH}^- + \text{OH}^* \quad (1)
\]

which can react within nanoseconds with anything adjacent. The role of Fe is absolutely vital here. Superoxide can also react with ferric Fe in the Haber–Weiss reaction to produce Fe(II) again, thereby effecting redox cycling, and meaning the ‘iron’ is catalytic (Fig. 6):

\[
\text{O}_2^- + \text{Fe(III)} \rightarrow \text{O}_2 + \text{Fe(II)} \quad (2)
\]

In addition O2•− can release ‘catalytic’ Fe from Fe-S clusters in certain proteins and from ferritin, another way in which it can promote the Fenton reaction. Note that other reactions can produce OH• anaerobically. Because OH• is so reactive it is not really observable in its free form; its action is detected via products of molecules with which it has reacted. These include 8-oxo-guanine derivatives (itself formed from peroxynitrite, possibly formed more commonly via superoxide), 4-hydroxy-nonenal, and many others reviewed previously.

In evaluating the antioxidant potency of ERG or anything else, it is molecules such as these that are normally assessed. Although the literature is somewhat scattered and heterogeneous, it seems clear that as well as hydroxyl radicals, ERG can also react with and detoxify, or prevent the formation of, singlet oxygen, ozone, superoxide, peroxide, hypochlorite, and peroxynitrite. Consequently, it is a potent antioxidant.
Fig. 5. Superoxide and peroxide are produced by 1- and 2-electron reduction of dioxygen by the mammalian respiratory chain. For a colour figure, see the online version of the paper.

Fig. 6. Catalytic roles of unliganded iron in hydroxyl radical production via the Fenton and Haber–Weiss reactions. This can be stopped by ensuring that iron is fully liganded. For a colour figure, see the online version of the paper.
Roles in the producer

Although it is not a priori certain that they would be the same in both producer and consumer organisms, it is of interest, before looking at higher organisms, to consider the roles of ERG in the producer organisms themselves. In the case of C. purpurea, the ERG serves as an antioxidant to neutralise a plant host defence response based on \( \text{H}_2\text{O}_2 \) that would otherwise inhibit the production of its conidia(252,253). In M. tuberculosis and other mycobacteria(254), and also in other actinobacteria(255) and in fungi(247,256,257), it is clear that ERG can have a role as an antioxidant(66,258–260) and also act as a buffer against reductive stress(261). In nature many organisms can be subjected to oxidative stress, and produce a variety of molecules to combat it(262–270). This also seems true of mushrooms(271,272), where ERG is typically the main antioxidant(273–279), and where it may also inhibit the oxidative enzyme tyrosinase(276). Given suggestions that the purpose of secondary metabolic formation is to serve as a signalling molecule in different cells of the producer organism, i.e. as a pheromone(277), it is interesting to note that this may also involve crosstalk of ERG(279), due in part to the complex networks in which it may be embedded(278). The same is true of the imidazole thiol-containing ovothiol(279,280).

In a similar vein, and although outwith our scope here, we note the potential of other antioxidant natural products such as curcumin(281–283), Betaines are generally seen as nutritionally beneficial(284), and many are compatible solutes(288–295) defined as solutes whose accumulation assists the survival of the organism when undergoing various kinds of stress such as osmotic or thermal stress. However, of these, only ERG is seen as a major antioxidant. Although a variety of foodstuffs such as oats(294,295) contain ERG because they take it up from exogenous sources, it is really mushrooms that are the prime sources for humans(18,294). Mushrooms typically contain different amounts(275,298–300) of ERG(301–303) and these can vary with physiological or environmental conditions(301–303). Those with the highest amounts include oyster mushrooms (Pleurotus spp., up to 4 mg/g DM)(306), the golden oyster Pleurotus citrinopileatus with 10–65 mg/g DM(307,308), and shiitake (Lentinula edodes, about 1 mg/g DM), while of those more common outside Asia, porcini or cep (Boletus edulis, > 7 mg/g DM), stand out(6,294,303).

However, even common field or ‘button’ mushrooms, Agaricus bisporus, contain some 0–4 mg/g DM(275,299,309,310). Note too that tempel(h), the result of a solid substrate Rhizopus oligosporus fermentation(310–314), also contains high levels of ERG(301). Mushrooms may also be a significant benefit to those seeking a meat-free diet as they can be made to share certain organoleptic features with meat(315,316). Notably, the production of cultivated, edible mushrooms worldwide has increased more than 30-fold since 1978, whereas the population has only increased by about 1.7-fold during the same period(10,317).

Some studies that have demonstrated nutritional/health benefits of mushrooms and their antioxidant activity(125,271,318–351) did not always seek to deconstruct these into their constituents such as ERG, but ERG is clearly the chief mushroom antioxidant. We note too that some effects may be dependent on the composition of the gut microflora(352), that are of course themselves likely to be changed by ERG, just as they are by many other non-antibiotic drugs(353).

Safety

Producer organisms such as mushrooms are well known to make many secondary metabolites, some of which can be highly toxic(354–356) and by various mechanisms(357). Notwithstanding the highly variable intake between individuals(358), however, a number of high-dose studies have indicated that ERG is safe for mammalian consumption at levels far in excess of those likely to be encountered in foodstuffs(125,313,359,360), and it has been declared safe by relevant committees such as those of the European Food Standards Agency(361,362). It also lacks any detectable mutagenicity or genotoxicity in such assays, even at very high doses(363,364).

Analytics

Leaving aside early efforts such as the colorimetric methods of Hunter(365), of Melville and colleagues(366,367) and of Carlsson et al.(368), a variety of analytical methods have been proposed(369), mostly involving capillary electrophoresis(369,370) or chromatography(369,370) coupled to absorbance(371–374), fluorescence detection(375–378), electrochemical detection(379) or MS(380,381,382). A useful feature is that ERG is unusually stable, in that anhydrous ERG decomposes only at 275–276°C(76), allowing its isolation at temperatures close to that of boiling water(72). As judged by the reversibility of its acid–base titration(383), it is also stable to extremes of pH.

Industrial purification of glycine betaine is done by extraction with water(384) and subsequent ion exchange chromatography(384,385) which can be done in simulated moving bed fashion(386). Glycine betaine can then be crystallised(387). As glycine betaine is structurally similar to ERG, this straightforward industrial process could potentially be adapted for ERG.

Serum and other concentrations

While most ERG is inside erythrocytes in whole blood(6,121,122,129,387), there have been a number of measurements of ERG concentrations in serum. Unsurprisingly it varies with diet(388,389), starvation(390), age(391,392) and other factors, including diseases of oxidative stress(393), with typical values of 20–100 μg/mL. A detailed list is provided by Cheah & Halliwell(41), a smaller listing is given in Table 3. Interestingly, ERG is also present in seminal fluid(394–396) and human breast milk(397). Any possible correlation with male fertility(398) seems not to have been established, though there were no negative effects(399) and ERG improved oocyte quality and maturation.
in cows and sheep(399). ERG is also present in eye lens, where its concentration is lower in individuals with cataracts(400).

**Metabolism and excretion**

ERG is metabolised and excreted only slowly(360,371,401,402). In a recent and detailed study, Cheah et al.(131) administered 5–25 mg daily doses of ERG to healthy volunteers for 7 d. There was little urinary excretion (≤4 %), and the main metabolites were hernyine, plus lesser amounts of 5-methyl-ERG, whose concentrations were well correlated with the level of ERG and the dose of ERG given. Similar observations were made in mice(131). Various other biomarkers of oxidative stress (for example, 8-iso-PGF2α from lipid peroxidation) were lowered concomitantly in the human study, attesting to the antioxidant functions of ERG in vivo, although in this case the healthy young subjects were probably not suffering from oxidative stress. There was also quite some variation in uptake between individuals, presumably reflecting variation in their expression of SLC22A4. Was also quite some variation in uptake between individuals, presumably reflecting variation in their expression of SLC22A4.

**Apparent fitness benefits and bioactivities of ERG and the role of SLC22A4**

Given the great technical difficulties associated, because of its ubiquity, with withholding ergothioneine from a human or animal diet, one means of ‘removing’ ERG from a host is to remove the ERG transporter by genetic means. This has in fact been done in mice(401); such SLC22A4−/− mice had immeasurably low levels of ERG relative to controls, and were much more sensitive to oxidative stress than were the wild type. Similar effects were observed in Caenorhabditis elegans(411). Polymorphisms in SLC22A4, of which there can be many(177,412–415), under selection(410), have also been associated with ischaemic stroke(417), erythroid differentiation(418), hearing loss(412), rheumatoid arthritis(120,180,419–427), lupus(428), Crohn’s disease(401,429–430), hearing loss(412), type 1 diabetes(437) and diabetic embryopathy(438). The expression of SLC22A4 can itself be modulated by other factors, including by PPAR-α activity(439). The very diversity of these diseases speaks naturally to a broad and common underlying cause, the easiest of which involves mechanisms of oxidative stress, inflammation and cell death.

**Mechanisms of action**

It has become common to discover a binding of a small molecule to another molecule such as a protein, and assume that this interaction, leading to activation or inhibition of the target, constitutes ‘the’ mechanism of action of the small molecule at a physiological level. Unfortunately this is rarely the case, and known drugs, despite often being selected for inhibiting potently a specific molecular target(417), have, on average, six known binding targets(440). When these interactions ramify through a complex and non-linear biochemical network it can be hard to apportion the effects of a small exogenous molecule between the various interactions(441–443).

A standard view of systems or network biology (for example, Kell(444) and Kell & Knowles(445)) develops these ideas in four stages. In stages 1 and 2 we simply recognise the actors and the interactions between them at a qualitative level. Stages 3 and 4 then seek to describe the equations reflecting individual steps and the values of the parameters of those equations. Armed with these we can make an ordinary or, if spatial resolution within a compartment is required, a partial differential equation model of the system. This can then be run and the sensitivities of each step determined(446–448). We are very far from this last part, and so studies of the effects of ERG have in general(449) been rather descriptive in nature. Many have been at the level of processes rather than mechanisms, and they have been reviewed in detail(5,80). Table 4 and Fig. 7 provide a selection of determinants that have been shown to change their concentrations or activities when ERG is added to the system of interest. In many cases it is not at all clear what the proximate mechanisms are. Note as just one example that the highly promiscuous transcription factor NF-κB(500–502), whose frequency-dependent activity directly affects the expression of hundreds of enzymes(455,454), is itself redox-sensitive(455–458), and is affected by ERG(459,600), while NF-κB increases the rates of SC22A4 transcription(419). Thus, deconstructing the many possible direct and consequential interactions of ERG with proteins, whether these are simply a consequence of its provision of a more reducing environment, is likely to be a formidable task. In a similar vein, the effects of ERG on the microbiomes of the hosts are likely to be significant, but do not yet seem to have been studied.

It seems clear that the chief role of ERG, via a variety of mechanisms, including directly, is to serve as an antioxidant and cellular protectant against various kinds of reactive oxygen and N species.

**Cytoprotection**

At a high level, ERG is seen as an excellent cytoprotectant against all kinds of cellular insults(3,4,6,124). We split some of the more detailed analyses into subdivisions in the following few sections.

### Table 3. Concentrations of ergothioneine in human serum

| Study | Concentration | Study |
|-------|---------------|-------|
| Crohn’s disease | 7 μg/ml | (401) |
| Healthy volunteer | 38 μg/ml | (401) |
| Healthy 1–10 years | 15–20 μg/ml | (387) |
| Healthy 11–18 years | 37 μg/ml | (387) |
| Healthy 19–60 years | 23–30 μg/ml | (387) |
| Healthy middle-aged and older | Median 1 μM = 229 ng/ml, Inverse correlation with age | (571) |
| Mice on normal diet | 58 μg/ml | (131) |

* Molecular weight = 229.3, so 1 mm = 229 mg/l.
Oxidative stress can be defined and measured in many ways(461–468), but is broadly taken to involve a dysregulation in the various redox systems of the organism of interest, coupled to the production of various ‘reactive oxygen species’, principally peroxide, superoxide, hydroxyl radical, and singlet oxygen. ERG has been shown to decrease oxidative stress in the liver and kidney of rats(469), rescued cells from β-amyloid-induced apoptotic death(231), protected against palmitic acid-induced cell death(470), mercuric chloride-induced cellular dysfunction(471), and prevented Cu-induced oxidative damage to DNA(472,473). It is protective against the oxidation of various kinds of molecule(474,475), including astaxanthin(475), and accumulates in a guinea-pig model of non-alcoholic fatty liver disease(476), massively so in mouse models of myocardial infarction and heart failure(477), and in a rat model of optic nerve crush(478). It serves to resist H2O2-induced cell death(479), pyrogallol-induced toxicity(124), cisplatin(480) or oxaliplatin-induced toxicity, glucose-induced senescence(246,482), as well as lipopolysaccharide-induced inflammation(483). In particular, it is protective against ischaemia–reperfusion injury(484–486), and may have uses in prolonging the lifetime of stored blood(487). Probably such antioxidant activities are at the core of its biological benefits.

Table 4. Biological properties whose expression or activity varies on exposure of a biological system to ergothioneine (ERG) or a modulation of SLC22A4 activity

| Determinand                                      | System                                      | Comments                                      | Selected reference(s) |
|--------------------------------------------------|---------------------------------------------|-----------------------------------------------|------------------------|
| Cataract formation induced by glucocorticoid     | Developing chick embryo                    | ERG inhibits                                  | (572)                  |
| Cell death                                       | Human neuronal hybridoma cell line           | H2O2 challenge                                | (251)                  |
| Cell injury                                      | Rat pheochromocytoma cells                  | Protection from amyloid-β-induced cell death  | (521)                  |
| Cell proliferation                               | K562 cells                                  | Methylglyoxal challenge                       | (573)                  |
| Cell proliferation                               | Caco-2 cells                                | Involvement of SLC22A4                       | (418)                  |
| Diabetic embryopathy                             | Rats                                        | Involvement of SLC22A4                       | (420)                  |
| DNA damage in mitochondria                       | Caenorhabditis elegans                      | Protection from amyloid-β-induced cell death  | (521)                  |
| Embryo development                               | RAW 264.7, HaCaT, PC12 cells                | ERG reduced it to control levels              | (574)                  |
| Embryo quality and maturation                    | Sheep                                       | ERG reduced it to control levels              | (3)                    |
| Excitotoxicity caused by N-methyl-D-aspartate    | Cows                                        | Improvement, despite non-uptake of ERG        | (399,575)              |
| Glycolysis                                       | Erythrocytes                                 | H2O2 challenge                                | (572)                  |
| Hepatocytic injury induced by CCl4               | Hepatocytes                                 | Protection, also by β-hydroxy derivative      | (579)                  |
| Immune modulation                                | Mouse macrophages                           | Skewing towards a Th17 response              | (580)                  |
| Immunotherapy                                    | Tumour cells                                | Improved vaccine responses by dampening      | (581)                  |
| IL-8                                            | Alveolar macrophages                        | Cytotoxic T-lymphocyte suppression            | (480)                  |
| Fe incorporation into protoporphyrin            | Erythrocyte fractions                       | Said to keep Fe reduced; does not seem to     | (562)                  |
| Kidney fibrosis                                  | Mice                                        | have been confirmed                          | (582)                  |
| Lipid peroxidation                               | HeLa, RAW 264.7, HaCaT, PC12 cells          | In vitro                                      | (3)                    |
| Lung injury                                      | Rats                                        | Free radical initiated with anthracyclines    | (580)                  |
| Memory                                           | C57BL/6J mice                               | Cytokine treatment; damage prevented by ERG   | (565)                  |
| Metal ion chelation                              | Co++, Cu++, Ni++, Zn++                      | Direct and within enzymes                     | (527)                  |
| Neuronal differentiation                         | Neuronal progenitor cells                   | IR measurements                              | (586)                  |
| Mutagenesis protection                           | Multiple                                    | NMR                                           | (586)                  |
| NF-κB                                           | M47A cells                                  | Chelation prevents DNA damage                 | (473)                  |
| NF2                                              | HaCaT skin cells                            | Chelation prevents DNA damage                 | (472)                  |
| S-nitrosoglutathione catalisim                   | Multiple                                    | Often involving singlet oxygen               | (586,588)              |
| S6K1 mTOR and neurotrophin 4/5-TrkB             | Neural stem cells                           | Anti-apoptotic following UV irradiation      | (549)                  |
| Sirtuin and Sirt6                               | Endothelial cells                           | ERG stimulates                               | (590)                  |
| Sperm motility                                  | Bears                                       | Rapid induction after ERG exposure           | (594)                  |
| Sickle cell anaemia                              | Endothelial cells                           | ERG is protective                            | (596)                  |
| siRNA, small interfering RNA; mTOR, mammalian target of rapamycin; SIRT, sirtuin.

Oxidative stress

Oxidative stress can be defined and measured in many ways(461–468), but is broadly taken to involve a dysregulation in the various redox systems of the organism of interest, coupled to the production of various ‘reactive oxygen species’, principally peroxide, superoxide, hydroxyl radical, and singlet oxygen. ERG has been shown to decrease oxidative stress in the liver and kidney of rats(469), rescued cells from β-amyloid-induced apoptotic death(451), protected against palmitic acid-induced cell death(470), mercuric chloride-induced cellular dysfunction(471), and prevented Cu-induced oxidative damage to DNA(472,473). It is protective against the oxidation of various kinds of molecule(474,475), including astaxanthin(475), and accumulates in a guinea-pig model of non-alcoholic fatty liver disease(476), massively so in mouse models of myocardial infarction and heart failure(477), and in a rat model of optic nerve crush(478). It serves to resist H2O2-induced cell death(479), pyrogallol-induced toxicity(124), cisplatin(480) or oxaliplatin-induced toxicity, glucose-induced senescence(246,482), as well as lipopolysaccharide-induced inflammation(483). In particular, it is protective against ischaemia–reperfusion injury(484–486), and may have uses in prolonging the lifetime of stored blood(487). Probably such antioxidant activities are at the core of its biological benefits.
Ergothioneine as a therapeutic for chronic inflammatory diseases?

Inflammation and oxidative stress go hand in hand\(^{(3)}\), since reactive oxygen species (and materials such as bacterial cell wall components that can lead to their generation\(^{(206,488)}\)), lead to the production of inflammatory cytokines. Although a great many chronic, inflammatory diseases are recognised as having an oxidative stress component\(^{(223)}\), the history of treating them with antioxidants such as ascorbate has largely been a litany of failure, with the treatment arm often giving worse prognoses than the placebo\(^{(6,223,489–501)}\). Arguably this is because nominally antioxidant molecules such as ascorbate have complex, multi-electron redox chemistry, and can in fact act as pro-oxidants\(^{(502,503)}\), especially in the presence of free Fe\(^{(208,213)}\) or Cu\(^{(504)}\). This is not an issue with ERG, however, partly because it can chelate them, and ERG levels are decreased, or ERG has been proposed as a useful antioxidant, in diseases such as acute respiratory distress syndrome\(^{(505)}\), CVD\(^{(506,507)}\), chronic obstructive pulmonary disease\(^{(223)}\), pre-eclampsia\(^{(40)}\) (see also Turner et al\(^{(120)}\)), overhydrated hereditary stomatocytosis\(^{(508)}\), and is significantly lowered in others such as certain leukaemias\(^{(121,122)}\). The evidence for this comes from a variety of sources, including metabolite measurements in human subjects\(^{(121,122,509)}\), and intervention studies in both animals\(^{(505)}\) and cell lines\(^{(5,124,506)}\). In particular, there is a notable relationship between ERG consumption and longevity (Fig. 6 in Beelman et al\(^{(10)}\)), while in a 3236-participant Swedish study, ERG was the metabolite most strongly connected to a ‘health conscious food pattern’ and was associated with a lower risk of coronary disease (hazard ratio (HR) per 1 SD increment of ERG, HR = 0.85; \(P = 0.01\)), cardiovascular mortality (HR = 0.79; \(P = 0.002\)) and overall mortality (HR = 0.86; \(P = 4 \times 10^{-5}\))\(^{(509)}\).

Fig. 7. Overview of some of the effects of ergothioneine in mammalian systems. For a colour figure, see the online version of the paper.

**Neurological diseases and cognitive function**

Mushrooms have been shown to have very substantial effects on cognitive function\(^{(341,348,510–513)}\), and this is mainly ascribed to their ERG content, that also deases with the age of the consumer\(^{(591)}\). The kinds of evidence include both double-blind, placebo-controlled clinical trials\(^{(341)}\) and observational...
(cross-sectional) studies in both humans\(^{510-512}\) and rodents\(^{513}\). Thus, consuming 1-5 mushroom servings per week was associated with a halving of the incidence of mild cognitive impairment (a precursor of Alzheimer’s dementia), while intake of nine servings per week was associated with a five-fold decrease\(^{518}\). Note, however, that at least one mushroom trial indicated no measurable benefits in healthy young physical education students\(^{514}\). Brain and serum ERG levels are also markedly different in Parkinson’s disease\(^{515}\), reviewed in Hang et al.\(^{516}\), Shao & Le\(^{517}\) and Shah & Duda\(^{518}\), and even in sudden infant death syndrome\(^{519}\), and ERG has been shown to be protective against β-amyloid-induced neuronal injury\(^{520}\) and cytotoxicity\(^{521}\). It can also act as an antidepressant\(^{522}\). The evidence for this comes from direct studies\(^{520}\) and feeding experiments\(^{522}\) in mice, as well as via the reduction of β-amyloid peptide in a transgenic \textit{C. elegans} model\(^{521}\). As mentioned above, SLC22A4 polymorphisms are associated with ischaemic stroke\(^{417}\).

### Use of ergothioneine as an antioxidant in processed foodstuffs

Just as living beings exploit antioxidants, most foodstuffs can also be oxidised to produce taints or other undesirable products\(^{523-525}\), often via the Fenton reaction\(^{528-526}\). ERG inhibits polyphenoloxidases\(^{527}\), and thus ERG has been used in the feed of the shrimp \textit{Marsupenaeus japonicus} to prevent melanosis during storage\(^{528}\), while ERG-rich mushroom extract has also been used to prevent melanosis in post-harvest storage of the crab \textit{Chionoecetes japonicus}\(^{529}\). Thus, one can also envisage a role for ERG, whether natural or added, in extending shelf lives and commercial value\(^{525,528,475,528-539}\). The thermostability of ERG is of particular importance here.

### Use of ergothioneine in cosmetics

Just as processed foodstuffs ‘age’, so do tissues such as the skin, and although the same principles apply\(^{560}\), it is common to refer to nutraceuticals that are also aimed at having cosmetic benefits as ‘cosmeceuticals’\(^{541-545}\). Here too, ERG has been widely used\(^{545-547}\), since much skin damage is caused by UV-mediated reactive oxygen species production\(^{548}\), indeed, ERG is known as a skin protectant\(^{240-244,549-551}\).

### Role of ergothioneine as a cofactor?

Although it is possible that the role of ERG lies simply in being an antioxidant capable of mopping up hydroxyl radicals and other reactive oxygen species, especially in prokaryotes\(^{50,66,93,254,255,258-260,552,553}\), the roles of most other vitamins involve interaction with proteins, often as cofactors. This is also true for mycothiol\(^{75,554-556}\), though that molecule can also serve as a signal and nutrient resource\(^{557}\). However, despite many hypotheses\(^{558,559}\), the only example of ERG acting as a cofactor known to date is an involvement in the biosynthesis of lincomycin\(^{560,561}\). An early paper\(^{562}\) implying an involvement of ERG in the maintenance of a reduced state of Fe in Hb, although apparently accurate, does not seem to have been followed up to date.

### Conclusions

There is increasing awareness that health may be enhanced via the consumption of substances that either have no recommended intake or are taken at levels greater than normal, and such substances are commonly referred to as nutraceuticals. ERG, a potent and effective antioxidant, seems to be an important nutraceutical, and we rehearse a very broad literature, involving a great many cells, tissues and organisms, to that effect. The chief source of ERG in the human diet is mushrooms (usually the fruiting bodies of Basidiomycetes). The fact that a specific transporter known as SLC22A4 has evolved and been selected to effect ERG uptake in all known animals suggests strongly that ERG is of benefit to its consumers. While the evidence that ERG may be a useful nutraceutical as a preventive or palliative for various inflammatory diseases is extensive, it is mostly circumstantial rather than definitive, though many examples exist of the benefits of mushrooms in combating the results of oxidative stress.

Without mechanisms, finding that the concentration of a dietary metabolite X is low in disease Y does not mean that giving it might be of benefit in the prevention, delay or cure of that disease, although cases can clearly be made when X is a vitamin, or oxidative stress is known to be a damaging component of Y\(^{568}\). Thus far, we lack examples in which ERG is found both to be low in individuals with a particular syndrome and where exogenous administration effects functional improvements, although – as reviewed above – we often have one or the other.

To assess definitively any health benefits of ERG, the ‘gold standard’ of randomised controlled trials may take time and money, but – as with mushrooms\(^{535,563}\) – are beginning. One trial with pure ERG has been registered\(^{564}\).

### Note added in proof

A recent paper indicates that ERG relieves the effects seen in a rat model of the pregnancy disorder pre-eclampsia\(^{597}\).

### Acknowledgements

We thank the Biotechnology and Biological Sciences Research Council (BBSRC) (grants no. BB/R000093/1 and no. BB/P009042/1) and the Novo Nordisk Foundation (grant no. NNFI06C1011517) for financial support.

D. B. K. decided to bring together the multifaceted contributions of the various authors listed. Their previous contributions to ergothioneine and antioxidant biology may be seen in the references cited. All authors contributed to and approved the final manuscript.

I. B., S. A. v. d. H. and D. B. K. are named inventors on a patent application involving the biotechnological production of \(\text{L-}\)ergothioneine in yeast. For the other authors, there are no conflicts of interest.
References

1. Kraemer K, Semba RD, Eggersdorfer M, et al. (2012) Introduction: the diverse and essential biological functions of vitamins. Ann Nutr Metab 61, 185–191.
2. Semba RD (2012) The discovery of the vitamins. Int J Vitam Nutr Res 82, 310–315.
3. Paul BD & Snyder SH (2010) The unusual amino acid \(t\)-ergothioneine is a physiologic cytoprotectant. Cell Death Differ 17, 1134–1140.
4. Cheah IK & Halliwell B (2012) Ergothioneine: an adaptive antioxidant for the protection of injured tissues? A hypothesis. Biochem Biophys Res Commun 417, 245–250.
5. Halliwell B, Cheah IK & Drum CL (2016) Ergothioneine, an adaptive antioxidant in management of diabetes: a review of randomized clinical trials and their meta-analyses. Br J Clin Pharmacol 83, 165–171.
6. Aziz MS (2015) Prolonging healthy aging: longevity vitamins and proteins. Proc Natl Acad Sci U S A 112, 10836–10844.
7. Kerley RN, McCarthy C, Kell DB, et al. (2019) The potential therapeutic effects of ergothioneine in pre-eclampsia. Free Radic Biol Med 132, 357–356.
8. Ames BN (2018) Adapting aging: longevity vitamins and proteins. Nutrients 2, 611–625.
9. Bahadoran Z, Mirmiran P & Azizi F (2013) Dietary polyphenols as potential nutraceuticals in management of diabetes: a review. J Diabetes Metab Disord 12, 43.
10. Bang JH, Mirmiran P & Azizi F (2013) Dietary polyphenols as potential nutraceuticals in management of diabetes: a review. J Diabetes Metab Disord 12, 43.
11. Cencic A & Chingwaru W (2010) The role of functional foods, nutraceuticals, and bioactive compounds in mushrooms: a recipe for healthy aging? Nutr Today 54, 16–22.
12. Cencic A & Chingwaru W (2010) The role of functional foods, nutraceuticals, and bioactive compounds in mushrooms: a recipe for healthy aging? Nutr Today 54, 16–22.
13. Ogle WO, Speisman RB & Ormerod BK (2013) Potential of detectable blood pressure-lowering effect: a review of mechanistic and clinical evidence. Prog Neuropsychopharmacol Biol Psychiatry 35, 887–895.
14. Goggi R, Vaughan-Thomas A, Clegg PD, et al. (2005) Nutraceutical therapies for degenerative joint diseases: a critical review. Crit Rev Food Sci Nutr 45, 145–164.
15. Aruoma OI, Coles LS, Landes B, et al. (2006) An in vitro study on the free radical scavenging capacity of ergothioneine: comparison with reduced glutathione, uric acid and trolox. Free Radic Biol Med 78, 793–800.
16. Franzoni F, Colognato R, Galetta F, et al. (2006) An in vitro study on the free radical scavenging capacity of ergothioneine: comparison with reduced glutathione, uric acid and trolox. Free Radic Biol Med 78, 793–800.
17. Semba RD (2012) The discovery of the vitamins. Int J Vitam Nutr Res 82, 310–315.
18. Halliwell B, Cheah IK & Tang RMY (2018) Ergothioneine: an adaptive antioxidant for the protection of injured tissues? A hypothesis. Biochem Biophys Res Commun 470, 245–250.
19. Beelman RB, Kalaras MD, John P, et al. (2019) Micronutrients and bioactive compounds in mushrooms: a recipe for healthy aging? Nutr Today 54, 16–22.
20. Halliwell B, Cheah IK & Tang RMY (2018) Ergothioneine – a diet-derived antioxidant with therapeutic potential. FEBs Lett 592, 357–356.
21. Anjum OA, Coles LS, Landes B, et al. (2012) Functional benefits of ergothioneine and fruit- and vegetable-derived nutraceuticals: overview of the supplemental issue contents. Prev Med 54, Suppl., S4–S8.
22. Rathore H, Prasad S & Sharma S (2017) Mushroom nutraceuticals for improved nutrition and better human health: a review. PharamNutrition 5, 35–46.
23. Espin JC, García-Conesa MT & Tomáš-Barberán FA (2007) Nutraceuticals: facts and fiction. Phytochemistry 68, 2986–3008.
24. Sharif MK & Khalid R (2018) Nutraceuticals: myths versus realities. In Therapeutic Foods, vol. 8, pp. 3–21 [AM Holban and AM Grumezescu, editors]. Cambridge, MA: Academic Press.
25. Singh S, Razak MA, Sangam SR, et al. (2018) The impact of functional food and nutraceuticals in health. In Therapeutic Foods, vol. 8, pp. 23–47 [AM Holban and AM Grumezescu, editors]. Cambridge, MA: Academic Press.
22. Spindler SR, Mote PL & Flegal JM (2014) Lifespan effects of simple and complex nutraceutical combinations fed isocalorically to mice. Age (Dordr) 36, 705–718.
23. Poddar K, Kolge S, Bezman L, et al. (2011) Nutraceutical supplements for weight loss: a systematic review. Nutr Clin Pract 26, 539–552.
24. Camfield DA, Sarris J & Berk M (2011) Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence. Prog Neuropsychopharmacol Biol Psychiatry 35, 887–895.
25. Goggi R, Vaughan-Thomas A, Clegg PD, et al. (2005) Nutraceutical therapies for degenerative joint diseases: a critical review. Crit Rev Food Sci Nutr 45, 145–164.
26. Naveen J & Baskaran V (2018) Antidiabetic plant-derived nutraceuticals: a critical review. Eur J Nutr 57, 1275–1299.
27. Orr SL & Venkateswaram S (2014) Nutraceuticals in the prophylaxis of pediatric migraine: evidence-based review and recommendations. Cephalalgia 34, 508–583.
28. Orr SL (2016) Diet and nutraceutical interventions for headache management: a review of the evidence. Cephalalgia 36, 1112–1133.
29. Tanret C (1909) A new base taken from rye ergot, ergothio- 
ene. Ann Chim Phys 18, 114–124.
30. Tanret C (1909) A new base taken from rye ergot, ergothio- 
eine. C.R Hebod Acad Sci 149, 222–224.
31. Barger G & Ewins AJ (1911) The constitution of ergothioneine: a betaine related to histidine. J Chem Soc 99, 2356–2341.
32. Serpoli L, Castaldo D, Casale R, et al. (2015) An uncommon redox behavior sheds light on the cellular anti- 
oxidant properties of ergothioneine. Free Radic Biol Med 79, 228–236.
33. Franzoni F, Colognato R, Galetta F, et al. (2006) An in vitro study on the free radical scavenging capacity of ergothioneine: comparison with reduced glutathione, uric acid and trolox. Biomed Pharmacother 60, 453–457.
34. Hand CE, Taylor NJ & Honek JF (2005) Novel thiols of prokaryotes. Trends Microbiol 13, 335–347.
35. Hand CE & Honek JF (2005) Biological chemistry of naturally occurring thiols of microbial and marine origin. J Nat Prod 68, 293–308.
36. Fahey RC (2013) Glutathione analogs in prokaryotes. Biochim Biophys Acta 1830, 3182–3198.
37. Neirand KJ, Dolanm SC & Doyle S (2015) Endogenous cross- 
talk of fungal metabolites. Front Microbiol 5, 732.
38. Fahey RC (2001) Novel thiols of prokaryotes. Annu Rev Microbiol 55, 335–356.
39. Jacob C (2006) A scent of therapy: pharmacological implications of natural products containing redox-active sulfur atoms. Nat Prod Rep 23, 851–863.
40. Clark WM (1960) Oxidation-reduction Properties of Organic Systems. Baltimore, MD: The Williams and Wilkins Co.
41. Walz D (1979) Thermodynamics of oxidation–reduction reac- 
tions and its application to bioenergetics. Biochim Biophys Acta 505, 279–353.
42. Reyes AM, Pedre B, De Armas MI, et al. (2018) Chemistry and redox biology of mycothiol. Antioxid Redox Signal 28, 487–504.
43. Marra SV, Van Laer K, Messens J, et al. (2016) Thiol redox and \(pK_a\) properties of mycothiol, the predominant low- 
molecular-weight thiol cofactor in the actinomycetes. Chembiochemistry 17, 1689–1692.
44. Kell DB & Morris JG (1979) Oxidation–reduction properties of coenzyme M (2-mercaptoethane sulphonate) at the mercury electrode. FEBS Lett 108, 481–484.
129. Mitsuyama H & May JM (1999) Uptake and antioxidant effects of ergothioneine in human erythrocytes. *Clin Sci (Lond)* **97**, 407–411.

130. Gründermann D, Hartfingers S, Golz S, et al. (2005) Discovery of the ergothioneine transporter. *Proc Natl Acad Sci USA* **102**, 5256–5261.

131. Tang RMY, Cheah IK, Yew TSK, et al. (2018) Distribution and accumulation of dietary ergothioneine and its metabolites in mouse tissues. *Sci Rep* **8**, 1601.

132. Nikodemus D, Lizzi D, Bach M, et al. (2011) Paramount levels of ergothioneine transporter SLC22A4 mRNA in boar seminal vesicles and cross-species analysis of ergothioneine and glutathione in seminal plasma. *J Physiol Pharmacol* **62**, 411–419.

133. Kaneko I, Takeuchi Y, Yamaoka Y, et al. (1980) Quantitative determination of ergothioneine in plasma and tissues by TLC-densitometry. *Chem Pharm Bull (Tokyo)* **28**, 3093–3097.

134. Shires TK, Brummel MC, Pulido JS, et al. (1997) Ergothioneine distribution in bovine and porcine ocular tissues. *Comp Biochem Physiol C Pharmacol Toxicol Endocrinol* **117**, 117–120.

135. Crossland J, Mitchell J & Woodruff GN (1966) The presence of ergothioneine in the central nervous system and its probable identity with the cerebellar factor. *J Physiol* **182**, 427–438.

136. Nakamichi N, Taguchi T, Hosotani H, et al. (2012) Functional expression of carnitine/organic cation transporter OCTN1 in mouse brain neurons: possible involvement in neuronal differentiation. *Neurochem Int* **61**, 1121–1132.

137. Vermeulen E & Vermeersch P (2012) Hepcidin as a biomarker for the diagnosis of iron metabolism disorders: a review. *Acta Clin Belg* **67**, 190–197.

138. Ganz T & Nemeth E (2011) The hepaticin–ferroportin system as a therapeutic target in anemias and iron overload disorders. *Hematol Am Soc Hematol Educ Program* **2011**, 538–542.

139. Ganz T & Nemeth E (2012) Hepcidin and iron homeostasis. *Biochim Biophys Acta* **1823**, 1434–1443.

140. Nemeth E & Ganz T (2009) The role of hepcidin in iron metabolism. *Acta Haematol* **122**, 78–86.

141. Reichert CO, da Cunha J, Levy D, et al. (2017) Hepcidin: homeostasis and diseases related to iron metabolism. *Acta Haematol* **137**, 220–230.

142. Kell DB, Swainston N, Pir P, et al. (2015) Membrane transporter engineering in industrial biotechnology and whole-cell biocatalysis. *Trends Biotechnol* **33**, 237–246.

143. Dobson PD & Kell DB (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? *Nat Rev Drug Discov* **7**, 205–220.

144. Kell DB & Dobson PD (2009) The cellular uptake of pharmaceutical drugs is mainly carrier-mediated and is thus an issue not so much of biophysics but of systems biology. In: *Proceedings of the International Beilstein Symposium on Systems Chemistry*, pp. 149–168 [MG Hicks and C Kettner, editors]. Berlin: Logos Verlag.

145. Kell DB, Dobson PD & Oliver SG (2011) Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. *Drug Disc Today* **16**, 704–714.

146. Kell DB, Dobson PD, Bilbland E, et al. (2013) The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. *Drug Disc Today* **18**, 218–229.

147. Kell DB (2013) Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening, and knowledge of transporters: where drug discovery went wrong and how to fix it. *FEBS J* **280**, 5957–5980.

148. Kell DB & Oliver SG (2014) How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipid bilayer diffusion. *Front Pharmacol* **5**, 231.

149. Kell DB (2015) The transporter-mediated cellular uptake of pharmaceutical drugs is based on their metabolite-likeness and not on their bulk biophysical properties: towards a systems pharmacology. *Perspect Sci* **6**, 66–83.

150. Kell DB (2016) How drugs pass through biological cell membranes – a paradigm shift in our understanding? *Beilstein Journal of Medicinal Chemistry* **2**, no. 5.

151. Giacomini KM, Huang SM, Tweedie DJ, et al. (2010) Membrane transporters in drug development. *Nat Rev Drug Discov* **9**, 215–236.

152. Dickens D, Rädisch S, Chidzuza GN, et al. (2018) Cellular uptake of the atypical antipsychotic clozapine is a carrier-mediated process. *Mol Pharm* **15**, 3557–3572.

153. César-Razquin A, Snijder B, Frappier-Brinton T, et al. (2015) A call for systematic research on solute carriers. *Cell* **162**, 478–487.

154. Hediger MA, Clemenson B, Burrier RE, et al. (2015) The ABCs of membrane transporters in health and disease (SLC series): Introduction. *Mol Aspects Med* **34**, 95–107.

155. Anonymous (2019) SLC Tables. http://www.bioparadigms.org/slc/intro.htm (accessed August 2019).

156. Chen Z, Shi T, Zhang L, et al. (2016) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. *Cancer Lett* **370**, 153–164.

157. Koepsell H (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. *Mol Aspects Med* **34**, 413–435.

158. Pochini L, Galluccio M, Scalise M, et al. (2019) OCTN: a small transporter subfamily with great relevance to human pathophysiology, drug discovery, and diagnostics. *SLAS Discov* **24**, 89–110.

159. Garg N, Kaponco C, Lim YW, et al. (2015) Mass spectral similarity for untargeted metabolomics data analysis of complex mixtures. *Int J Mass Spectrom* **377**, 719–717.

160. LiXS, Wang Z, Caija T, et al. (2018) Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk. *JCI Insight* **3**, 99096.

161. Coene KLM, Khijitmans LAJ, van der Heeft E, et al. (2018) Next-generation metabolic screening: targeted and untargeted metabolomics for the diagnosis of inborn errors of metabolism in individual patients. *J Inherit Metab Dis* **41**, 357–353.

162. Tautenhahn R, Cho K, Uriboomthai W, et al. (2012) An accelerated workflow for untargeted metabolomics using the METLIN database. *Nature Biotechnol* **30**, 826–828.

163. Dunn WB, Broadhurst D, Begley P, et al. (2011) Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. *Nat Protoc* **6**, 1060–1083.

164. Dunn WB, Erban A, Weber RJ, et al. (2013) Mass appeal: metabolic identification in mass spectrometry-focused untargeted metabolomics. *Metabolomics* **9**, Suppl. 1, S44–S66.

165. Heinzmann SS, Brown JJ, Chen Q, et al. (2010) Metabolic profiling strategy for discovery of nutritional biomarkers: proline betaine as a marker of citrus consumption. *Am J Clin Nutr* **92**, 436–443.

166. Lang R, Lang T, Bader M, et al. (2017) High-throughput quantitation of proline betaine in foods and suitability as a valid biomarker for citrus consumption. *J Agric Food Chem* **65**, 1613–1619.

167. Lloyd AJ, Beckmann M, Favé G, et al. (2011) Proline betaine and its biotransformation products in fasting urine samples
are potential biomarkers of habitual citrus fruit consumption. Br J Nutr 106, 812–824.

168. Gasteiger J (2003) Basic Chemoinformatics: A Textbook. Weinheim: Wiley/VCH.

169. Bachr P, Giersiefer S, Bach M, et al. (2009) Substrate discrimination by ergothioneine transporter SLC22A4 and carnitine transporter SLC22A5: gain-of-function by interchange of selected amino acids. Biochim Biophys Acta 1788, 2594–2602.

170. Grilli S, Harlfinger S, Pal S, et al. (2007) Probing the substrate specificity of the ergothioneine transporter with methimazole, hencrycine, and organic cations. Biochem Pharmacol 74, 309–416.

171. Gründemann D (2012) The ergothioneine transporter controls and indicates ergothioneine activity – a review. Prev Med 54, Suppl., S71–S74.

172. Tschirka J, Kreisor M, Betz J, et al. (2013) Application of the ergothioneine transporter. Drug Metab Dispos 41, 779–785.

173. Shimizu T, Masuo Y, Takahashi S, et al. (2015) Organic cation transporter OCTN1-mediated uptake of food-derived antioxidant ergothioneine into infiltrating macrophages during intestinal inflammation in mice. Drug Metab Pharmacokinet 30, 231–239.

174. Yabuuchi H, Tamai I, Nezu J, et al. (2011) Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther 334, 65–72.

175. Akamine T, Koyanagi S, Kusunose N, et al. (2015) Dosing time-dependent changes in the analgesic effect of pregabalin in mice. J Pharmacol Exp Ther 354, 774–780.

176. Shimizu T, Kijjima A, Masuo Y, et al. (2015) Gene ablation of carnitine/organic cation transporter 1 reduces gastrointestinal absorption of 5-aminoisocytocine in mice. Biol Pharm Bull 38, 1580–1584.

177. Tamai I (2013) Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). Biopharm Drug Dispos 34, 29–44.

178. Nakamura T, Yoshida K, Yabuuchi H, et al. (2008) Functional characterization of ergothioneine transport by rat organic cation/carnitine transporter OCTN1 (SLC22A4). Biol Pharm Bull 31, 1580–1584.

179. Darghouth D, Giarratana MC, Oliveira L, et al. (2016) Bioengineered and native red blood cells from cord blood exhibit the same metabolic profile. Haematologica 101, e220–e222.

180. Taubert D, Lazar A, Grimberg G, et al. (2006) Association of rheumatoid arthritis with ergothioneine levels in red blood cells: a case control study. J Rheumatol 33, 2139–2145.

181. Indiveri C, Galluccio M, Scalise M, et al. (2013) Strategies of bacterial over expression of membrane transporters relevant in human health: the successful case of the three members of OCTN subfamily. Mol Biotechnol 54, 724–736.

182. Frigeni M, Iacobazzi F, Yin X, et al. (2016) Wide tolerance to amino acids substitutions in the OCTN1 ergothioneine transporter. Biochim Biophys Acta 1860, 1334–1342.

183. Nigam SK (2018) The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. Annu Rev Pharmacol Toxicol 58, 663–687.

184. Pochini L, Scalise M, Galluccio M, et al. (2013) OCTN cation transporters in health and disease: role as drug targets and assay development. J Biomol Screen 18, 851–867.

185. Wolf KK & Paine MF (2018) Metabolic barrier of the gastrointestinal tract. In Comprehensive Toxicology, 3rd ed., pp. 74–98 [C McQueen, editor]. Amsterdam: Elsevier.

186. Thul PJ, Åkesson L, Wiking M, et al. (2017) A subcellular map of the human proteome. Science 356, eaal3521.

187. Apostolova N & Victor VM (2015) Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications. Antioxid Redox Signal 22, 686–729.

188. Lamhounah AM & Tein I (2006) Novel localization of OCTN1, an organic cation/carnitine transporter, to mammalian mitochondria. Biochem Biophys Res Commun 345, 1315–1325.

189. Lamhounah AM, Hawkins CE, Tam C, et al. (2008) Expression patterns of the organic cation/carnitine transporter family in adult murine brain. Brain Dev 30, 31–42.

190. Xuan W, Lamhounah AM, Librach C, et al. (2005) Characterization of organic cation/carnitine transporter family in human sperm. Biochem Biophys Res Commun 334, 121–128.

191. Anonymous (2019) SLC22A4. https://www.proteinatlas.org/ENSG00000197208-SLC22A4/cell (accessed August 2019).

192. Skogs M, Stadler C, Schutter R, et al. (2017) Antibody validation in bioimaging applications based on endogenous expression of tagged proteins. J Proteome Res 16, 147–155.

193. Eilers F, Hober A, Linderbäck K, et al. (2018) Enhanced validation of antibodies for research applications. Nat Commun 9, 4130.

194. Rahia LA, Desai AA, Jhajh HS, et al. (2018) Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility. Biochem Eng J 137, 365–374.

195. Jain D & Salunke DM (2019) Antibody specificity and promiscuity. Biochem J 476, 433–447.

196. Edwards BM, Barash SC, Main VH, et al. (2003) The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BlyS. J Mol Biol 334, 103–118.

197. Vaughan TJ, Osbourn JK & Tempest PR (1998) Human antibody bodies by design. Nat Biotechnol 16, 535–539.

198. Michaud GA, Salcius M, Zhou F, et al. (2003) Analyzing antibody specificity with whole proteome microarrays. Nat Biotechnol 21, 1509–1512.

199. Palmieri F (2013) The mitochondrial transporter family SLC25: identification, properties and physiopathology. Mol Aspects Med 34, 465–484.

200. Palmieri F (2014) Mitochondrial transporters of the SLC25 family and associated diseases: a review. J Inherit Metab Dis 37, 565–575.

201. Anonymous (2019) Q9H015 tree in phylome 533. http://phylomdb.org/?q=search_tree&seqid=Q9H015 (accessed August 2019).

202. Anonymous (2019) GeneTree Image. http://www.ensembl.org/Multi/GeneTree/Image?gt=ENSG000004000154155 (accessed August 2019).

203. O’Hagan S & Kell DB (2017) Consensus rank orderings of molecular fingerprints illustrate the ‘most genuine’ similarities between marketed drugs and small endogenous human metabolites, but highlight exogenous natural products as the most important ‘natural’ drug transporter substrates. AIDMET DMPK 5, 85–125.

204. Chapy H, Smirnova M, Andre P, et al. (2014) Carrier-mediated cocaine transport at the blood–brain barrier as a putative mechanism in addiction liability. Int J Neuropsychopharmacol 18, pyu001.

205. Danchin A (2018) Bacteria in the ageing gut: did the taming of fire promote a long human lifespan? Environ Microbiol 20, 1966–1987.
The biology of ergothioneine 207

206. Kell DB & Pretorius E (2018) No effects without causes. The iron dysregulation and dormant microbes hypothesis for chronic, inflammatory diseases. *Biol Rev* 93, 1518–1557.

207. Butterfield DA & Halliwell B (2019) Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. *Nat Rev Neuosci* 20, 148–160.

208. Kell DB (2009) Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. *BMC Med Genomics* 2, 2.

209. Bahior BM (2000) Phagocytes and oxidative stress. *Am J Med* 109, 33–44.

210. Cave AC, Brewer AC, Narayananpanicker A, et al. (2006) NADPH oxidases in cardiovascular health and disease. *Antioxid Redox Signal* 8, 691–728.

211. Bedard K & Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. *Physiol Rev* 87, 245–313.

212. Wardman P & Candelas JP (1996) Fenton chemistry: an introduction. *Rad Res* 145, 523–531.

213. Kell DB (2010) Towards a unifying, systems biology understanding of iron. *Antioxid Redox Signal* 14, 825–889.

214. Winston GW, Feierman DE & Cederbaum AI (1984) The role of tyrosine. Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? *FEBS Lett* 182, 714–728.

215. Halliwell B (1997) What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? *FEBS Lett* 411, 157–160.

216. Kehrer JP (2000) *The Haber–Weiss reaction and mechanisms of toxicity. Toxicology* 149, 43–50.

217. Kell DB & Pretorius E (2014) Serum ferritin is an important disease marker, and is mainly a leakage product from damaged cells. *Metallomics* 6, 748–773.

218. Valachova K, Mach M, Duboviczky M, et al. (2019) The importance of ergothioneine synthesis in ancient time by organisms living in oxygen free atmosphere. *Med Hypotheses* 123, 72–73.

219. Migliore I, Fontana I, Colognato R, et al. (2005) Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer’s disease and in other neurodegenerative diseases. *Neurobiol Aging* 26, 587–595.

220. Ahsan H (2013) 3-Nitrotyrosine: a biomarker of nitrogen free radical species modified proteins in systemic autoimmune genic conditions. *Hum Immunol* 74, 1392–1399.

221. Bartesgghi S & Radi R (2018) Fundamentals on the biochemistry of peroxynitrite and protein tyrosine nitration. *Redox Biol* 14, 618–625.

222. Ryberg H & Gaidahl K (2007) Chromatographic and mass spectrometric methods for quantitative determination of 3-nitrotyrosine in biological samples and their application to human samples. *J Chromatogr B* 851, 160–171.

223. Rahman I (2012) Pharmacological antioxidant strategies as therapeutic interventions for COPD. *Biochim Biophys Acta* 1822, 714–728.

224. Aruoma OI, Whitman M, England TG, et al. (1997) Antioxidant action of ergothioneine: assessment of its ability to scavenge peroxynitrite. *Biochem Biophys Res Commun* 231, 389–391.

225. Halliwell B (1997) What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? *FEBS Lett* 411, 157–160.

226. Ferrer-Sueta G, Campolo N, Trujillo M, et al. (2018) Biochemistry of peroxynitrite and protein tyrosine nitration. *Chem Rev* 118, 1338–1408.

227. Petersen DR & Doorn JA (2004) Reactions of 4-hydroxynonenal with proteins and cellular targets. *Free Radic Biol Med* 37, 957–945.

228. Akanmu D, Cecchini R, Aruoma OI, et al. (1991) The antioxidant action of ergothioneine. *Arch Biochem Biophys* 288, 10–16.

229. Asmus KD, Benassourov RV, Bernier JL, et al. (1996) One-electron oxidation of ergothioneine and analogues investigated by pulse radiolysis: redox reaction involving ergothioneine and vitamin C. *Biochem J* 315, 625–629.

230. Motohashi N & Mori I (1986) Thiol-induced hydroxyl radical formation and scavenger effect of thiocarbamides on hydroxyl radicals. *J Inorg Biochem* 26, 205–212.

231. Ahsan H, Aruoma OI, Jeynes RS, et al. (2004) Ergothioneine rescues PC12 cells from β-amyloid-induced apoptotic death. *Free Radic Biol Med* 36, 288–299.

232. Chaudière J & Ferrari-illici R (1999) Intracellular antioxidants: from chemical to biochemical mechanisms. *Food Chem Toxicol* 37, 949–962.

233. Oumari M, Goldfuss B, Stoffels C, et al. (2019) Regeneration of peroxynitrite after reaction with singlet oxygen. *Free Radic Biol Med* 134, 498–504.

234. Devasagayam TPA, Sundquist AR, Di Mascio P, et al. (1991) Activity of thiols as singlet molecular oxygen quenchers. *J Photochem Photobiol B* 5, 105–116.

235. Hartmann PE, Hartmann Z & Ault KT (1990) Scavenging of singlet molecular oxygen by imidazole compounds: high and sustained activities of carboxy terminal histidine dipeptides and exceptional activity of imidazole-4-actic acid. *Photochem Photobiol* 51, 59–66.

236. van der Broeke LT & Beyersbergen van-Henegouwen GM (1993) Thiols as potential UV radiation protectors: an in vitro study. *J Photochem Photobiol B* 17, 279–286.

237. Egorov S, Kurella EG, Boldyrev AA, et al. (1997) Quenching of singlet molecular oxygen by carnosine and related antioxidants. Monitoring 1270-nm phosphorescence in aqueous media. *Biochem Mol Biol Int* 41, 687–694.

238. Boldyrev A & Abe H (1999) Metabolic transformation of neuroepitide carnosine modifies its biological activity. *Cell Mol Neurobiol* 19, 163–175.

239. Dahl TA, Midden WR & Hartman PE (1988) Some prevalent biomolecules as defenses against singlet oxygen damage. *Photochem Photobiol* 47, 357–362.

240. Dong KK, Damaghi N, Kibitel J, et al. (2005) Searching for et al. (2010) A comparison of the relative antioxidant potency of l-ergothioneine and idebenone. *J Cosmet Dermatol* 6, 183–188.

241. Ohayashi K, Kurahara K, Okano Y, et al. (2005) l-Ergothioneine scavenges superoxide and singlet oxygen and suppresses TNF-α and MMP-1 expression in UV-irradiated human dermal fibroblasts. *J Cosmet Sci* 56, 17–27.

242. Stoffels C, Oumari M, Perrou A, et al. (2017) Ergothioneine stands out from hercynine in the reaction with singlet oxygen: resistance to glutathione and TRIS in the generation of specific products indicates high reactivity. *Free Radic Biol Med* 113, 385–394.

243. He QC, Krone K, Schild D, et al. (2004) The use of ozone as an oxidizing agent to evaluate antioxidant activities of natural substrates. *Skin Pharmacol Physiol* 17, 183–189.

244. Markova NG, Karaman-Jurukovska N, Dong KK, et al. (2009) Skin cells and tissue are capable of using l-ergothioneine as an integral component of their antioxidant defense system. *Free Radic Biol Med* 46, 1168–1176.
245. Nguyen TH, Nagasaka R & Ohshima T (2013) The natural anti-
oxidant ergothioneine: resources, chemical characterization, and ap-
lications. In Lipid Oxidation: Challenges in Food Systems, pp. 381–415 [A Logan, U Nienaber and X Pan, edi-
tors]. Urbana, IL: AOCS Press.

246. Servillo I, D’Onofrio N, Casale R, et al. (2017) Ergothioneine products derived by superoxide oxidation in endothelial cells exposed to high-glucose. Free Radic Biol Med 108, 8–18.

247. Bello MH, Barrera-Perez V, Morin D, et al. (2012) The Neurospora crassa mutant NeΔErg-1 identifies an ergothi-
oneine biosynthetic gene and demonstrates that ergothioneine enhances conidial survival and protects against peroxide toxicity during conidial germination. Fungal Genet Biol 49, 160–172.

248. Hartman PE (1990) Ergothioneine as antioxidant. Meth Enzymol 186, 310–318.

249. Asahi T, Wu X, Shimoda H, et al. (2016) The importance of antioxidants which play natural products in targeting cardiovascular diseases via Nrf2 pathway: novel molecular mechanisms and therapeutic approaches. Front Pharmacol 9, 1308.

250. Urquiaga I & Leighton F (2000) Plant polyphenol antioxidants and oxidative stress. Biol Res 33, 55–64.

251. Chen W, Jia Z, Pan MH, et al. (2016) Natural products for the prevention of oxidative stress-related diseases: mechanisms and strategies. Oxid Med Cell Longev 2016, 4628502.

252. Salehi B, Stojanović-Radić Z, Matejić J, et al. (2019) The thera-
petic potential of curcumin: a review of clinical trials. Eut J Med Chem 163, 527–545.

253. Gonçalves PB, Rameiro NC (2019) Multi-target natural products as alternatives against oxidative stress in chronic obstructive pulmonary disease (COPD). Eut J Med Chem 163, 911–931.

254. Jia ZQ, Anandh Babu PV, Chen W, et al. (2018) Natural prod-
ucts targeting on oxidative stress and inflammation: mecha-
nisms, therapies, and safety assessment. Oxid Med Cell Longev 2018, 6576093.

255. Davey HM & Kell DB (1996) Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analysis. Microbiol Rev 60, 641–696.

256. Savoie J-M, Minville N & Largeteau ML (2008) Radical-
saving properties of extracts from the white button mush-
room, Agaricus bisporus. J Sci Food Agric 88, 870–875.

257. Yokota ME, Frison PS, Marcante RC, et al. (2016) Iron translo-
cation in Pleurotus ostreatus basidiospores: production, bio-
availability, and antioxidant activity. Genet Mol Res 15.

258. Kozarski M, Klaus A, Jakovljevic D, et al. (2015) Antioxidants of edible mushrooms. Molecules 20, 19489–19525.

259. Zhao H, Zhang M, Liu Q, et al. (2018) A comprehensive screening shows that ergothioneine is the most abundant anti-
oxidant in the wild macrofungus Phylloporia ribis-Ryvarden. J Environ Sci Health C 36, 98–111.

260. Dubost NJ, Ou B & Beelman RB (2007) Quantification of polyphenols and ergothioneine in cultivated mushrooms and correlation to total antioxidant capacity. Food Chem 105, 727–735.

261. Gallagher L, Owens RA, Dolan SK, et al. (2012) Kinetics of ergothi-
oneine inhibition of mushroom tyrosinase. Appl Biochem Biotechnol 166, 259–267.

262. Kell DB, Kaprelyants AS & Grafen A (1995) On pheromones, social behaviour and the functions of secondary metabolism in bacteria. Trends Ecol Evolution 10, 126–129.

263. Gallagher L, Owens RA, Dolan SK, et al. (2012) The Aspergillus fumigatus protein Glik protects against oxidative stress and is essential for gliotoxin biosynthesis. Eukaryot Cell 11, 1226–1238.

264. Song H, Her AS, Raso F, et al. (2014) Cysteine oxidation reactions catalyzed by a mononuclear non-heme iron enzyme (OvoA) in ovotool biosynthesis. Org Lett 16, 2122–2125.

265. Castellano I & Seebeck FP (2018) On ovotool biosynthesis and biological roles: from life in the ocean to therapeutic potential. Nut Prod Rep 35, 1241–1250.

266. Vázquez-Fresno R, Rosana ARR, Sajed T, et al. (2019) Herbs and spices- biomarkers of intake based on human interven-
tion studies – a systematic review. Genes Nutr 14, 18.

267. Menon VP & Sudheer AR (2007) Antioxidant and anti-
inflammatory properties of curcumin. Adv Exp Med Biol 595, 105–125.

268. Abrhams S, Haylett WL, Johnson G, et al. (2019) Antioxidant effects of curcumin in models of neurodegeneration, aging, oxidative and nitrosative stress: a review. Neuroscience 406, 1–21.

269. Li H, Sureda A, Devkota HP, et al. (2019) Curcumin, the golden spice in treating cardiovascular diseases. Biotechnol...
Ado. 2019, S0734-9750(19)30010-2 (publication ahead of print version 1 February 2019).

285. Saneti M & Saberi-Demneh A (2019) Effect of curcumin on memory impairment: a systematic review. *Phytomedicine* **52**, 98–106.

286. Tomesh MA, Hadianamrei R & Zhao X (2019) A review of curcumin and its derivatives as anticancer agents. *Int J Mol Sci* **20**, E1053.

287. Pekkinnen J, Rosa-Sibakov N, Micard V. et al. (2015) Amino acid-derived betaines dominate as urinary markers for rye bran intake in mice fed high-fat diet – a nontargeted metabolomics study. *Mol Nutr Food Res* **59**, 1550–1562.

288. Kempf B & Bremer E (1998) Uptake and synthesis of compatible solutes as microbial stress responses to high-osmolality environments. *Arch Microbiol* **170**, 319–330.

289. Roberts MF (2005) Organic compatible solutes of halotolerant and halophilic microorganisms. *Saltine Systems* **1**, 5.

290. Wani SH, Singh NB, Haribhushan A, et al. (2012) Mycelial compatible solute transporter multiplicity in *Lentinula edodes* (higher Basidiomycetes) with high ergothioneine content. *Int J Med Mushrooms* **15**, 267–275.

291. Tepwong P, Giri A & Ohshima T (2012) Effect of mycelial fermentation of *Lentinula edodes* (J. Lge) Imbach (Agaricomycetideae). *Int J Med Mushrooms* **16**, 105–112.

292. Sanei M & Saberi-Demneh A (2019) Effect of curcumin on memory impairment: a systematic review. *Phytomedicine* **52**, 98–106.

293. Liang CH, Ho KJ, Huang LY, et al. (2013) Antioxidant properties of fructifying bodies, mycelia, and fermented products of the culinary-medicinal king oyster mushroom, *Pleurotus eryngii* (higher Basidiomycetes), with high ergothioneine content. *Int J Med Mushrooms* **15**, 396–401.

294. Chen SY, Ho KJ, Hsieh YJ, et al. (2012) Contents of lowstatin, γ-aminobutyric acid and ergothioneine in mushroom fruiting bodies and mycelia. *JWFT Sci Technol* **47**, 274–278.

295. Chen SY, Ho KJ, Sasaki F, et al. (2012) Mycobial enhancement of ergothioneine by submerged cultivation of mushroom mycelia and its application as an antioxidative compound. *Food Chem* **131**, 247–258.

296. Wang Y, Gapstur SM, Carter BD, Fahnert B (2012) Using folding promoting agents in the biology of ergothioneine. *Adv Nutr Food Sci* **476**, 6466–6474.

297. Dubost NJ, Beelman RB, Holick MF, et al. (2012) Generation of potentially bioactive ergosterol-derived products following pulsed ultraviolet light exposure of mushrooms (*Agaricus bisporus*). *Food Chem* **135**, 396–401.

298. Lin SY, Chien SC, Wang SY, et al. (2015) Submerged cultivation of mycelium with high ergothioneine content from the culinary-medicinal golden oyster mushroom, *Pleurotus citrinopileatus* (higher Basidiomycetes). *Int J Med Mushrooms* **17**, 749–761.

299. Chen SY, Ho KJ, Hsieh YJ, et al. (2012) Contents of lowstatin, γ-aminobutyric acid and ergothioneine in mushroom fruiting bodies and mycelia. *JWFT Sci Technol* **47**, 274–278.

300. Liang CH, Ho KJ, Huang LY, et al. (2013) Antioxidant properties of fructifying bodies, mycelia, and fermented products of the culinary-medicinal king oyster mushroom, *Pleurotus eryngii* (higher Basidiomycetes), with high ergothioneine content. *Int J Med Mushrooms* **15**, 267–275.

301. Lin SY, Chien SC, Wang SY, et al. (2016) Nonvolatile taste components and antioxidant properties of fruiting body and mycelium with high ergothioneine content from the culinary-medicinal golden oyster mushroom *Pleurotus citrinopileatus* (Agaricomycetes). *Int J Med Mushrooms* **18**, 689–698.

302. Chen SY, Ho KJ, Hsieh YJ, et al. (2012) Contents of lowstatin, γ-aminobutyric acid and ergothioneine in mushroom fruiting bodies and mycelia. *JWFT Sci Technol* **47**, 274–278.

303. Kalaras MD, Beelman RB & Elias RJ (2012) Effects of postharvest pulsed UV light treatment of white button mushrooms (*Agaricus bisporus*) on vitamin D-2 content and quality attributes. *J Agric Food Chem* **60**, 220–225.

304. Kalaras MD, Beelman RB, Holick MF, et al. (2012) Generation of potentially bioactive ergosterol-derived products following pulsed ultraviolet light exposure of mushrooms (*Agaricus bisporus*). *Food Chem* **135**, 396–401.

305. Sanei M & Saberi-Demneh A (2019) Effect of curcumin on memory impairment: a systematic review. *Phytomedicine* **52**, 98–106.

306. Liang CH, Ho KJ, Huang LY, et al. (2013) Antioxidant properties of fructifying bodies, mycelia, and fermented products of the culinary-medicinal king oyster mushroom, *Pleurotus eryngii* (higher Basidiomycetes), with high ergothioneine content. *Int J Med Mushrooms* **15**, 267–275.

307. Lin SY, Chien SC, Wang SY, et al. (2015) Submerged cultivation of mycelium with high ergothioneine content from the culinary-medicinal golden oyster mushroom, *Pleurotus citrinopileatus* (higher Basidiomycetes). *Int J Med Mushrooms* **17**, 749–761.

308. Lin SY, Chien SC, Wang SY, et al. (2016) Nonvolatile taste components and antioxidant properties of fruiting body and mycelium with high ergothioneine content from the culinary-medicinal golden oyster mushroom *Pleurotus citrinopileatus* (Agaricomycetes). *Int J Med Mushrooms* **18**, 689–698.

309. Chen SY, Ho KJ, Hsieh YJ, et al. (2012) Contents of lowstatin, γ-aminobutyric acid and ergothioneine in mushroom fruiting bodies and mycelia. *JWFT Sci Technol* **47**, 274–278.

310. Peñaloza W, Davey CL, Hedger JN, et al. (1991) Stimulation by potassium ions of the growth of *Rhizopus oligosporus* during liquid- and solid-substrate fermentations. *World J Microbiol Biotechnol* **7**, 260–268.

311. Peñaloza W, Davey CL, Hedger JN, et al. (1992) Physiological studies on the solid-state quinoa tempe fermentation, using on-line measurements of fungal biomass production. *J Sci Food Agric* **59**, 227–235.

312. Karyadi D & Lukito W (1996) Beneficial effects of tempeh in cardiovascular protection: nuts, soy, lentils and tempe. *Asia Pac J Clin Nutr* **5**, 174–180.

313. Lukito W (2001) Candidate foods in the Asia-Pacific region for enhancing properties of mushrooms in meat-based dishes *Adv Nutr Food Sci* **805**, 97–109.

314. Nout MJR & Kiers JL (2005) Tempe fermentation, innovation and functionality: update into the third millennium. *J Appl Microbiol* **98**, 789–805.

315. Guinard JX, Myrdal Miller A, Mills K, et al. (2016) Consumer acceptance of dishes in which beef has been partially substituted with mushrooms and sodium has been reduced. *Appetite* **105**, 449–459.

316. Myrdal Miller A, Mills K, Wong T, et al. (2014) Flavor-enhancing properties of mushrooms in meat-based dishes in which sodium has been reduced and meat has been partially substituted with mushrooms. *J Food Sci* **79**, S179S–S180S.

317. Royse DJ, Baars J & Tan Q (2017) Current overview of mushroom production in the world. *Edible and Medicinal Mushrooms: Technology and Applications*, pp. 5–14 [DC Zied & A Pardo-Giménez, editors]. New York: Wiley-Blackwell.

318. Gallego P, Rojas A, Falcón G, et al. (2019) Water-soluble extracts from edible mushrooms (*Agaricus bisporus*) as inhibitors of hepatitis C viral replication. *Food Funct* **10**, 3758–3767.

319. Schmitz LRK (2015) Bioavailability and antioxidant effect of ergothioneine in human blood. *MalarBol Res Pap* **6**, 174–183.

320. Dogan A, Dalar A, Sadullahoglu C, et al. (2018) Investigation of the protective effects of horse mushroom (*Agaricus arvensis* Schaeff.) against carbon tetrachloride-induced oxidative stress in rats. *Mol Biol Rep* **45**, 787–797.

321. Khattak K, Mahtab H, Khanam PA, et al. (2007) Oyster mushroom reduced blood glucose and cholesterol in diabetic subjects. *Myxomycetis Medic* **16**, 94–99.
322. Hess J, Wang Q, Gould T, et al. (2018) Impact of *Agaricus bisporus* mushroom consumption on gut health markers in healthy adults. *Nutrients* **10**, E1402.

323. Chaturvedi VK, Agarwal S, Gupta KK, et al. (2018) Medicinal mushroom: boon for therapeutic applications. *J Biotech* **8**, 334.

324. Moro C, Palacios I, Lozano M, et al. (2012) Anti-inflammatory activity of methanolic extracts from edible mushrooms in LPS activated RAW 264.7 macrophages. *Food Chem* **150**, 350–355.

325. Guillamón E, García-Lafuente A, Lozano M, et al. (2010) Edible mushrooms: role in the prevention of cardiovascular diseases. *Fitoterapia** **81**, 715–725.

326. Friedman M (2015) Chemistry, nutrition, and health-promoting properties of *Hericium erinaceus* (lion’s mane) mushroom fruiting bodies and mycelia and their bioactive compounds. *J Agric Food Chem* **63**, 7108–7125.

327. Moon B & Lo YM (2014) Conventional and novel applications of edible mushrooms in today’s food industry. *J Food Process Pres** **38**, 2146–2153.

328. Tang C, Hoo PC, Tan LT, et al. (2016) Golden needle mushroom: a culinary medicine with evidenced-based biological activities and health promoting properties. *Front Pharmacol** **7**, 474.

329. Jayakumar T, Sakhivel M, Thomas PA, et al. (2008) *Pleurotus ostreatus*, an oyster mushroom, decreases the oxidative stress induced by carbon tetrachloride in rat kidneys, heart and brain. *Chem–Biol Interact* **176**, 108–120.

330. Jayakumar T, Thomas PA, Sheu JR, et al. (2011) *In vitro* and *in vivo* antioxidant effects of the oyster mushroom *Pleurotus ostreatus*. *Food Res Int** **44**, 851–861.

331. Jayakumar T, Thomas PA, Ramesh E, et al. (2010) An extract of the *Pleurotus ostreatus* mushroom bolsterst the glutathione redox system in various organs of aged rats. *J Med Food** **13**, 771–778.

332. Rahman MA, Abdulllah N & Aminudin N (2017) Corroborative assessment of mushroom as the graceful ageing and lifespan promoting agent. *Biointerface Res App** **7**, 2072–2083.

333. Rahman MA, Abdulllah N & Aminudin N (2016) Interpretation of mushroom as a common therapeutic agent for Alzheimer’s disease and cardiovascular diseases. *Crit Rev Biotechnol** **36**, 1131–1142.

334. Feeney MJ, Dwyer J, Hasler-Lewis CM, et al. (2014) Mushrooms and health summit proceedings. *J Nutr** **144**, 1128S–11368.

335. Feeney MJ, Miller AM, Roupas P (2014) Mushrooms – biologically distinct and nutritionally unique: exploring a ‘third food kingdom’. *Nutr Today** **49**, 301–307.

336. Kawaguchi Y, Nirengi S, Kotani K, Rahman MA, Abdullah N & Aminudin N (2016) Interpretation of mushroom as a common therapeutic agent for Alzheimer’s disease and cardiovascular diseases. *Crit Rev Biotechnol** **36**, 1131–1142.

337. Benson KF, Ager DM, Landes B, et al. (2012) Improvement of joint range of motion (ROM) and reduction of chronic pain after consumption of an ergothioneine-containing nutritional supplement. *Prev Med** **54**, Suppl., S83–S89.

338. Gargano ML, van Griensven LJJD, Isikhuemen OS, et al. (2017) Medicinal mushrooms: valuable biological resources of high exploitation potential. *Plant Biosystems** **151**, 548–565.

339. Khan MA & Tania M (2012) Nutritional and medicinal importance of *Pleurotus* mushrooms: an overview. *Food Rev Int** **28**, 313–329.

340. Calvo MS, Mehotra A, Beelman RB, et al. (2016) A retrospective study in adults with metabolic syndrome: diabetic risk factor response to daily consumption of *Agaricus bisporus* (white button mushrooms). *Plant Foods Hum Nutr** **71**, 245–251.

341. Mori K, Inatomi S, Ouchi K, et al. (2009) Improving effects of the mushroom *Yamabushitake* (*Hericium erinaceus*) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. *Phytoph Res** **23**, 367–372.

342. Roncero-Ramos I & Delgado-Andrade C (2017) The beneficial role of edible mushrooms in human health. *Curr Opin Food Sci** **14**, 122–128.

343. Reis F, Martins A, Vasconcelos MH, et al. (2017) Functional foods based on extracts or compounds derived from mushrooms. *Trends Food Sci Tech** **66**, 48–62.

344. Soković M, Glamolića J, Ćirić A, et al. (2018) Mushrooms as sources of therapeutic foods. In *Therapeutic Foods*, vol. 8, pp. 141–178 [Mary Holman and AM Grumezescu, editors]. Cambridge, MA: Academy Press.

345. Grovato Salinario A, Pennisi M, Di Paola R, et al. (2018) Neuroinflammation and neurodegeneration in the pathogenesis of Alzheimer’s disease and Alzheimer-linked pathologies: modulation by nutritional mushrooms. *Inmun Ageing** **15**, 8.

346. Valverde ME, Hernandez-Perez T & Paredes-Lopez O (2015) Edible mushrooms: improving human health and promoting quality life. *Int J Microbiol** **2015**, 376387.

347. Muszyńska B, Gzyrwacz-Kisielewska A, Kala K, et al. (2018) Anti-inflammatory properties of edible mushrooms: a review. *Food Chem** **243**, 573–581.

348. Feng L, Cheah IK, Ng MM, et al. (2019) The association between mushroom consumption and mild cognitive impairment: a community-based cross-sectional study in Singapore. *J Alzheimers Dis** **68**, 197–203.

349. Poddar KH, Ames M, Hsin-Jen C, et al. (2013) Positive effect of mushrooms substituted for meat on body weight, body composition, and health parameters. A 1-year randomized clinical trial. *Appetite** **71**, 379–387.

350. Hodge AM & Calvo MS (2019) Do bioactive components in non-animal food sources contribute to the beneficial health effect of a Japanese dietary pattern? *Public Health Nutr** **22**, 2469–2471.

351. Zembron-Lacny A, Gajewsiki M, Naczk M, et al. (2013) Effect of shitake (*Lentinus edodes*) extract on antioxidant and inflammatory response to prolonged eccentric exercise. *J Physiol Pharmacol** **64**, 249–254.

352. Jayachandran M, Xiao J & Xu B (2017) A critical review on health promoting benefits of edible mushrooms through gut microbiota. *Int J Mol Sci** **18**, E1934.

353. Maier L, Pruteanu M, Kuhn M, et al. (2018) Extensive impact of non-antibiotic drugs on human gut bacteria. *Nature** **555**, 623–628.

354. Schnutz M, Carron PN, Yersin B, et al. (2018) Mushroom poisoning: a retrospective study concerning 11-years of admissions in a Swiss emergency department. *Intern Emerg Med** **13**, 59–67.

355. Chan CK, Lam HC, Chiu SW, et al. (2016) Mushroom poisoning in Hong Kong: a ten-year review. *Hong Kong Med J** **22**, 124–130.

356. Verma N, Bhalla A, Kumar S, et al. (2014) Wild mushroom poisoning in north India: case series with review of literature. *J Clin Exp Hepatol** **4**, 361–365.

357. White J, Weinstein SA, De Haro L, et al. (2019) Mushroom poisoning: a proposed new clinical classification. *Toxicon** **157**, 53–65.

358. Ramirez-Martinez A, Wesolek N, Yadan JC, et al. (2018) Administration of pure ergothioneine to healthy human subjects: uptake, digestion, and excretion. *Intern Emerg Med** **23**, 367–372.

359. Cheah IK, Tang RMY, Yew Tsz, et al. (2017) Administration of pure ergothioneine to healthy human subjects: uptake, digestion, and excretion. *Intern Emerg Med** **23**, 367–372.
The biology of ergothioneine

metabolism, and effects on biomarkers of oxidative damage and inflammation. *Antioxid Redox Signal* **26**, 193–206.

361. Turck D, Bresson JL, Burlameque B, et al. (2016) Safety of synthetic \( \epsilon \)-ergothioneine (Ergonine (R)) as a novel food pursuant to Regulation (EC) No 258/97. *EFSA J* **14**, 4629.

362. Turck D, Bresson JL, Burlameque B, et al. (2017) Statement on the safety of synthetic \( \epsilon \)-ergothioneine as a novel food – supplementary dietary exposure and safety assessment for infants and young children, pregnant and breastfeeding women. *EFSA J* **15**, 5060.

363. Schauss AG, Vértesi A, Endres JR, et al. (2010) Evaluation of the safety of the dietary antioxidant ergothioneine using the bacterial reverse mutation assay. *Toxicology* **278**, 39–45.

364. Schauss AG, Béres E, Vértesi A, et al. (2011) The effect of ergothioneine on clastogenic potential and mutagenic activity: genotoxicity evaluation. *Int J Toxicol* **30**, 405–409.

365. Hunter G (1928) A new test for ergothioneine upon which is based a method for its estimation in simple solution and in blood-filtrates. *Biochem J* **22**, 4–10.

366. Melville DB & Lubschez R (1953) A method for the determination of ergothioneine in blood. *J Biol Chem* **200**, 275–285.

367. Carlsson J, Kierstan MP & Brocklehurst K (1974) A convenient spectrophotometric assay for the determination of \( \epsilon \)-ergothioneine in blood. *Biochem J* **139**, 257–242.

368. Sotgia S, Arru D, Sotgiu E, et al. (2016) Simultaneous determination of the main amino thiol and thione in human whole blood by CE and LC. *Bioanalytical* **8**, 945–951.

369. Sotgia S, Pisanu E, Pintus G, et al. (2013) Plasma \( \epsilon \)-ergothioneine measurement by high-performance liquid chromatography and capillary electrophoresis after a pre-column derivatization with 5-iodoacetamidofluorescein (5-IAF) and fluorescence detection. *PLOS ONE* **8**, e70374.

370. Zhou T, Liu Q, Jiang W, et al. (2012) A new strategy for quantitative analysis of ergothioneine in fermentation broth by RP-HPLC. *Lect Notes Elec Eng* **249**, 313–321.

371. Mayumi T, Kawano H, Sakamoto Y, et al. (1978) Studies on ergothioneine. V. Determination by high performance liquid chromatography and application to metabolic research. *Chem Pharm Bull (Tokyo)* **26**, 3772–3778.

372. Sotgia S, Zinellu A, Arru D, et al. (2015) Amniotic fluid \( \epsilon \)-ergothioneine concentrations in pregnant sheep after natural mating and transfer of vitrified/thawed *in-vitro* produced embryos. *Res Vet Sci* **102**, 238–241.

373. Liu Q, Zhang W, Wang H, et al. (2016) Validation of a HILLIC method for the analysis of ergothioneine in fermentation broth. *J Chromatogr A* **54**, 934–938.

374. Muda M, Pelizzoni F, Sello G, et al. (1988) Determination of ergothioneine in red blood cells by high-performance liquid chromatography. *J Chromatogr* **434**, 191–195.

375. Newton GL, Dorian R & Fahey RC (1981) Analysis of biological thiols: derivatization with monobromobimane and separation by reverse-phase high-performance liquid chromatography. *Anal Biochem* **114**, 385–387.

376. Bello MH, Mogannam JC, Morin D, et al. (2014) Endogenous ergothioneine is required for wild type levels of conidigenesis and conidial survival but does not protect against 254 nm UV-induced mutagenesis or kill. *Fungal Genet Biol* **73**, 120–127.

377. Fahey RC & Newton GL (1987) Determination of low-molecular-weight thiols using monobromobimane fluorescent labeling and high-performance liquid chromatography. *Methods Enzymol* **143**, 85–96.

378. Sotgia S, Pisanu E, Cambenna D, et al. (2014) Ultra-performance liquid chromatographic determination of \( \epsilon \)-ergothioneine in commercially available classes of cow milk. *J Food Sci* **79**, C1685–C1687.

379. Kuninori T & Nishiyama J (1991) Measurement of biological thiols and disulfides by high-performance liquid chromatography and electrochemical detection of silver mercaptide formation. *Anal Biochem* **197**, 19–24.

380. Kroepfl N, Francesconi KA, Schwerdle T, et al. (2019) Seleneneine and ergothioneine in human blood cells determined simultaneously by HPLC/ICPQQQ-MS. *J Anal At Spectrom* **34**, 127–134.

381. Bashir R (2017) Bio-analytical screening and characterization of antioxidant compounds using online liquid chromatography techniques and mass spectrometry. Thesis for Doctor of Philosophy, Swinburne University of Technology.

382. Sotgia S, Zinellu A, Pintus G, et al. (2013) Quantification of \( \epsilon \)-ergothioneine in whole blood by hydrophobic interaction ultra-performance liquid chromatography and UV-detection. *J Sep Sci* **36**, 1002–1006.

383. Sakurai H & Takeshima S (1977) Acid dissociation of 2-mercaptohistamine and its related compounds. *Talanta* **24**, 531–532.

384. Bessières MA, Gibon Y, Lefevre JC, et al. (1999) A single-step purification for glucose betaine determination in plant extracts by isocratic HPLC. *J Agric Food Chem* **47**, 3718–3722.

385. Kar JR & Singhal R (2017) Pilot scale production, kinetic modeling, and purification of glucose betaine and trehalose produced from *Actinopolyspora halophila* (MTCC 263) using acid whey: a dairy industry effluent. *Chem Eng Sci* **163**, 83–91.

386. Bubnik Z, Pour V, Gruberova A, et al. (2004) Application of continuous chromatographic separation in sugar processing. *J Food Eng* **61**, 509–513.

387. Kumosani TA (2001) \( \epsilon \)-Ergothioneine level in red blood cells of healthy human males in the Western province of Saudi Arabia. *Exp Mol Med* **33**, 20–22.

388. Baldrige RC & Lewis HB (1953) Diet and the ergothioneine content of blood. *J Biol Chem* **202**, 169–176.

389. Baldrige RC (1955) Blood ergothioneine and dietary oats. *J Nutr* **56**, 107–113.

390. Tenuya T, Chaleckis R, Takada J, et al. (2019) Diverse metabolic reactions activated during 58-hr fasting are revealed by non-targeted metabolomic analysis of human blood. *Sci Rep* **9**, 854.

391. Cheah IK, Feng L, Tang RMY, et al. (2016) Ergothioneine levels in an elderly population decrease with age and incidence of cognitive decline: a risk factor for neurodegeneration? *Biochem Biophys Res Commun* **478**, 162–167.

392. Yan S, Wu B, Lin Z, et al. (2009) Metabonomic characterization of aging and investigation on the anti-aging effects of total flavonoids of *Epimedium*. *Mol Biol* **55**, 1204–1213.

393. Dang VT, Shi Y & Werstuck G (2015) Comprehensive metabolomic analysis of diabetic atherosclerosis. *Can J Cardiol* **31**, S229.

394. Leone E, Mann T (1951) Ergothioneine in the seminal vesicle secretion. *Nature* **168**, 205–206.

395. Strzeżek R, Koziorowska-Gilun M, Kowalowka M, et al. (2009) Characteristics of antioxidant system in dog semen. *Pol J Vet Sci* **12**, 55–60.

396. Strzeżek R, Koziorowska-Gilun M, Kielczewski K, et al. (2015) Effect of dialysis of dog semen on sperm characteristics and some biochemical components of seminal plasma. *Pol J Vet Sci* **18**, 447–448.

397. Kenny LC & Kell DB (2018) Immunological tolerance, pregnancy and preeclampsia: the roles of semen microbes and the father. *Front Med Obs Gynecol* **4**, 239.

398. Forster R, Spézia F, Papineau D, et al. (2015) Reproductive safety evaluation of \( \epsilon \)-ergothioneine. *Food Chem Toxicol* **80**, 85–91.

399. Mishra A, Reddy J, Dhuli A, et al. (2018) \( \epsilon \)-Ergothioneine improves the developmental potential of *in vitro* sheep embryos.
without influencing OCTN1-mediated cross-membrane transcript expression. *Zygote* **26**, 149–161.

400. Shukla Y, Kulshreshtha OP & Khuteta KP (1981) Ergothioneine content in normal and senile human cataractous lenses. *Indian J Med Res* **73**, 472–475.

401. Kato Y, Kubo Y, Iwata D, et al. (2010) Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1. *Pharm Res* **27**, 832–840.

402. Chaleckis R, Murakami I, Takada J, et al. (2016) Individual variability in human blood metabolites identifies age-related differences. *Proc Natl Acad Sci U S A* **113**, 4252–4259.

403. Jose JM (2011) Ergothioneine degradation and properties of ergothionein from *Agrobacterium radiobacter*. BSc Thesis, Penn State University.

404. Kelly B, Appleman MD (1961) Degradation of ergothioneine by cell-free extracts of *Alcaligenes faecalis*. *J Bacteriol* **81**, 715–720.

405. Muramatsu H, Matsuo H, Okada N, Fennema D, Phillips IR & Shephard EA (2016) Trimethylamine.* Jose JM (2011) Ergothioneine degradation and properties of ergothionein from *Agrobacterium radiobacter*. BSc Thesis, Penn State University.

406. Murasawa H, Okada N, Fennema D, Phillips IR & Shephard EA (2016) Trimethylamine.* Jose JM (2011) Ergothioneine degradation and properties of ergothionein from *Agrobacterium radiobacter*. BSc Thesis, Penn State University.

407. Yamase Y, Horibe H, Ueyama C, Ben Said M, Grati M, Ishimoto T, Cheah IK, Ong RL, Gruber J, Maurer A, Leisinger F, Lim D, Mathieson I, Lazaridis I, Rohland N, Toh DSL, Koo SH, Limenta LMG, Mathieson I, Lazaridis I, Rohland N, et al. (2015) Association of joint erosion with SLC22A4 gene polymorphisms inconsistently associated with rheumatoid arthritis susceptibility. *Autoimmunity* **48**, 313–317.

408. Martínez A, Valdavía A, Pascual-Salcedo D, et al. (2006) Role of SLC22A4, SLC22A5, and RUNX1 genes in rheumatoid arthritis. *J Rheumatol* **33**, 842–846.

409. Yamada R, Tokuhiro S, Chang X, et al. (2004) SLC22A4 and RUNX1: identification of RA susceptible genes. *J Mol Med (Berl)* **82**, 558–564.

410. Lee YH, Bae SC, Kim JH, et al. (2015) Meta-analysis of SLC22A4 and RUNX1 polymorphisms: associations with rheumatoid arthritis susceptibility. *J Rheumatol* **74**, 351–358.

411. Otoroco G, Sánchez E, Gómez LM, et al. (2006) Study of the role of functional variants of SLC22A4, RUNX1 and SUMO4 in systemic lupus erythematosus. *Ann Rheum Dis* **65**, 791–799.

412. Taubert D, Grünberg G, Jung N, et al. (2005) Functional role of the 503F variant of the organic cation transporter OCTN1 in Crohn’s disease. *Gut* **54**, 1505–1506.

413. Taubert D, Jung N, Goessaer T, et al. (2009) Increased ergothioneine tissue concentrations in carriers of the Crohn’s disease risk-associated 503F variant of the organic cation transporter OCTN1. *Gut* **58**, 312–314.

414. Jung ES, Park HJ, Kong KA, et al. (2017) Association study between OCTN1 functional haplotypes and Crohn’s disease in a Korean population. *Korean J Physiol Pharmacol* **21**, 11–17.

415. Toh DSL, Koo SH, Limenta LM, et al. (2009) Genetic variations of the SLC22A4 gene in Chinese and Indian populations of Singapore. *Drug Metab Pharmacokinet* **24**, 475–481.

416. Toh DSL, Cheung PSG, Murray M, et al. (2013) Functional analysis of novel variants in the organic cation/ergothioneine transporter 1 identified in Singapore populations. *Mol Pharm* **10**, 2509–2516.

417. Mathieson I, Lazaridis I, Rohland N, et al. (2015) Genome-wide patterns of selection in 230 ancient Eurasians. *Nature* **528**, 499–503.

418. Yamase Y, Horibe H, Ueyama C, et al. (2015) Association of TOMM40 and SLC22A4 polymorphisms with ischemic stroke. *Biomed Rep* **3**, 491–498.

419. Nakamura T, Sugita S, Kobayashi D, et al. (2007) Decreased proliferation and erythroid differentiation of K562 cells by siRNA-induced depression of OCTN1 (SLC22A4) transporter gene. *Pharm Res* **24**, 1628–1635.

420. Maeda T, Hiyama M, Kobayashi D, et al. (2007) Mechanism of the regulation of organic cation/carnitine transporter 1 (SLC22A4) by rheumatoid arthritis-associated transcriptional factor RUNX1 and inflammatory cytokines. *Drug Metab Dispos* **35**, 394–401.

421. Tomehiro S, Yamada R, Chang X, et al. (2003) An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. *Nat Genet* **35**, 341–348.

422. Reglinski J, Smith WE & Sturrock RD (1988) Spin-echo 1H NMR detected response of ergothioneine to oxidative stress in the intact human erythrocyte. *Magn Reson Med* **6**, 217–223.

423. Takata Y, Inoue H, Sato A, et al. (2008) Replication of reported genetic associations of PADD4, FCR3, SLC22A4 and RUNX1 genes with rheumatoid arthritis: results of an independent Japanese population and evidence from meta-analysis of East Asian studies. *J Hum Genet* **53**, 163–173.

424. Barton A, Eyre S, Bowes J, et al. (2019) Investigation of the SLC22A4 gene (associated with rheumatoid arthritis in a Japanese population) in a United Kingdom population of rheumatoid arthritis patients. *Arthritis Rheum* **52**, 752–758.

425. Han TU, Lee HS, Kang C, et al. (2015) Association of joint erosion with SLC22A4 gene polymorphisms inconsistently associated with rheumatoid arthritis susceptibility. *Autoimmunity* **48**, 313–317.

426. Martínez A, Valdavía A, Pascual-Salcedo D, et al. (2006) Role of SLC22A4, SLC22A5, and RUNXI genes in rheumatoid arthritis. *J Rheumatol* **33**, 842–846.

427. Yamada R, Tokuhiro S, Chang X, et al. (2004) SLC22A4 and RUNXI: identification of RA susceptible genes. *J Mol Med (Berl)* **82**, 558–564.

428. Lee YH, Bae SC, Kim JH, et al. (2015) Meta-analysis of SLC22A4 and RUNXI polymorphisms: associations with rheumatoid arthritis susceptibility. *J Rheumatol* **74**, 351–358.

429. Otoroco G, Sánchez E, Gómez LM, et al. (2006) Study of the role of functional variants of SLC22A4, RUNXI and SUMO4 in systemic lupus erythematosus. *Ann Rheum Dis* **65**, 791–799.

430. Taubert D, Grünberg G, Jung N, et al. (2005) Functional role of the 503F variant of the organic cation transporter OCTN1 in Crohn’s disease. *Gut* **54**, 1505–1506.

431. Taubert D, Jung N, Goessaer T, et al. (2009) Increased ergothioneine tissue concentrations in carriers of the Crohn’s disease risk-associated 503F variant of the organic cation transporter OCTN1. *Gut* **58**, 312–314.

432. Jung ES, Park HJ, Kong KA, et al. (2017) Association study between OCTN1 functional haplotypes and Crohn’s disease in a Korean population. *Korean J Physiol Pharmacol* **21**, 11–17.

433. Lai Y, Xue J, Liu CW, et al. (2012) Crohn disease and genetic hitchhiking at IBD5. *Magn Reson Med* **68**, 1029–1033.

434. Mathieson I, Lazaridis I, Rohland N, et al. (2015) Genome-wide patterns of selection in 230 ancient Eurasians. *Nature* **528**, 499–503.

435. Yamase Y, Horibe H, Ueyama C, et al. (2015) Association of TOMM40 and SLC22A4 polymorphisms with ischemic stroke. *Biomed Rep* **3**, 491–498.

436. Leung E, Hong J, Fraser AG, et al. (2006) Polymorphisms in the organic cation transporter genes SLC22A4 and SLC22A5.
and Crohn’s disease in a New Zealand Caucasian cohort. *Immunolet Cell Biol* 84, 233–236.

437. Santiago JL, Martinez A, de la Calle H, et al. (2006) Evidence for the association of the SLC22A4 and SLC22A5 genes with type 1 diabetes: a case control study. *BMC Med Genet* 7, 54.

438. Zhao Z, Reece EA (2013) New concepts in diabetic embryopathy. *Clin Lab Med* 33, 207–253.

439. Wada E, Koyanagi S, Kusanose N, et al. (2015) Modulation of peroxisome proliferator-activated receptor-α activity by bile acids causes circadian changes in the intestinal expression of Octn1/Scl22a4 in mice. *Mol Pharmacol* 87, 314–322.

440. Mestre J, Gregori-Puigjané E, Valverde S, et al. (2009) The topology of drug-target interaction networks: implicit dependence on drug properties and target families. *Mol Biogest* 5, 1051–1057.

441. Kell DB (2006) Metabolomics, modelling and machine learning in systems biology: towards an understanding of the languages of cells. The 2005 Theodor Bücher lecture. *FEBS* **273**, 873–894.

442. Palsson BO (2015) *Systems Biology: Constraint-Based Reconstruction and Analysis*. Cambridge: Cambridge University Press.

443. Sastry AV, Gao Y, Szuhin R, et al. (2019) The *Escherichia coli* transcriptionome consists of independently regulated modules. *Nat Commun* 10, 5536.

444. Kell DB (2005) Metabolomics, machine learning and modelling: towards an understanding of the language of cells. *Bioresc Soc Trans* 33, 520–524.

445. Kell DB & Knowles JD (2006) The role of modeling in systems biology. In *System Modeling in Cellular Biology: From Concepts to Nuts and Bolts*, pp. 3–18 [Z Szallasi, J Stelling and V Periwal, editors]. Cambridge, MA: MIT Press.

446. Ihekwaebi AEC, Broomhead DS, Grinley R, et al. (2004) Sensitivity analysis of parameters controlling oscillatory signalling in the NF-κB pathway: the roles of IKK and IκBα. *Systems Biol* 1, 93–105.

447. Saltelli A, Tarantola S, Campolongo F, et al. (2004) Sensitivity Analysis in Practice: A Guide to Assessing Scientific Models. New York: Wiley.

448. Rand DA (2008) Mapping global sensitivity of cellular network dynamics: sensitivity heat maps and a global summation law. *J R Soc Interface* 5, Suppl. 1, S59–S60.

449. Kell DB & Oliver SG (2004) Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. *Bioessays* 26, 99–105.

450. Ledoux AG & Perkins ND (2014) NF-κB and the cell cycle. *Bioresc Soc Trans* 42, 76–81.

451. Perkins ND (2012) The diverse and complex roles of NF-κB subunits in cancer. *Nat Rev Cancer* 12, 121–132.

452. Shih RH, Wang CY & Yang CM (2015) NF-κB signaling pathways in neurological inflammation: a mini review. *Front Mol Neurosci* 8, 77.

453. Nelson DE, Ihekwaebi AEC, Elliott M, et al. (2004) Oscillations in NF-κB signalling control the dynamics of gene expression. *Science* 306, 704–708.

454. Ashall L, Horton CA, Nelson DE, et al. (2009) Pulsatile stimulation determines timing and specificity of NFκB-dependent transcription. *Science* 324, 242–246.

455. Buelna-Chontal M & Zazueta C (2013) Redox activation of Nrf2 & NF-κB: a double end sword? *Cell Signal* 25, 2548–2557.

456. Kaur U, Banerjee P, Bir A, et al. (2015) Reactive oxygen species, redox signalling and neuroinflammation in Alzheimer’s disease: the NF-κB connection. *Carr Top Med Chem* 15, 446–457.

457. Lepetos P, Papavassiliou KA & Papavassiliou AG (2019) Redox and NF-κB signaling in osteoarthritis. *Free Radic Biol Med* 132, 90–100.

458. Gao G & Dudley SC Jr (2009) Redox regulation, NF-κB, and atrial fibrillation. *Antioxid Redox Signal* 11, 2205–2277.

459. Xiao L, Zhao L, Li T, et al. (2006) Activity of the dietary anti-oxidant ergothioneine in a virus gene-based assay for inhibitors of HIV transcription. *Biofactors* 27, 157–165.

460. Rahman I, Gilmour PS, Jimenez LA, et al. (2003) Ergothioneine inhibits oxidative stress- and TNF-α-induced NF-κB activation and interleukin-8 release in alveolar epithelial cells. *Biochem Biophy Res Commun* 302, 860–864.

461. Agarwal A, Aponte-Mellado A, Premkumar BJ, et al. (2012) The effects of oxidative stress on female reproduction: a review. *Reprod Biol Endocrinol* 10, 49.

462. Aouache R, Biquard L, Vaiman D, et al. (2018) Oxidative stress in preeclampsia and placental diseases. *Int J Med* 19.

463. Wang J, Schipper HM, Velly AM, et al. (2015) Salivary biomarkers of oxidative stress: a critical review. *Free Radic Biol Med* 85, 95–104.

464. Schrag M, Mueller C, Zabel M, et al. (2013) Oxidative stress in blood in Alzheimer’s disease and mild cognitive impairment: a meta-analysis. *Neurobiol Dis* 59, 100–110.

465. Jones DP (2006) Redefining oxidative stress. *Antioxid Redox Signal* 8, 1865–1879.

466. Rice-Evans CA & Packer L (editors) (2003) *Flavonoids in Health and Disease*, 2nd ed. New York: Marcel Dekker.

467. Halliwell B & Gutteridge JMC (2006) *Free Radicals in Biology and Medicine*, 4th ed. Oxford: Oxford University Press.

468. Halliwell B & Gutteridge JMC (2015) *Free Radicals in Biology and Medicine*, 5th ed. Oxford: Oxford University Press.

469. Deiana M, Rosa A, Casu V, et al. (2004) Ergothioneine modulates oxidative damage in the kidney and liver of rats in vivo: studies upon the profile of polyunsaturated fatty acids. *Clin Nutr* 23, 183–193.

470. Lauretta A, Colognato R, Migliore L, et al. (2008) Modulation of palmitic acid-induced cell death by ergothioneine: evidence of an anti-inflammatory action. *Biofactors* 33, 237–247.

471. Gökçe G & Arun MZ (2014) Ergothioneine produces relaxation of an anti-inflammatory action. *Antioxid Redox Signal* 11, 2205–2277.

472. Gökçe G, Arun MZ & Ertna E (2018) Ergothioneine prevents endothelial dysfunction induced by mercury chloride. *Exp Ther Med* 14, 4697–4702.

473. Rai RK, Chalana A, Karri R, et al. (2019) Role of hydrogen bonding by thiones in protecting biomolecules from copper(I)-mediated oxidative damage. *Inorg Chem* 58, 6628–6638.

474. Zhu BZ, Mao L, Fan RM, et al. (2011) Ergothioneine prevents copper-induced oxidative damage to DNA and protein by forming a redox-inactive ergothioneine–copper complex. *Chem Res Toxicol* 24, 30–34.

475. Gökçe G & Arun MZ (2014) Ergothioneine produces relaxation in isolated rat aorta by inactivating superoxide anion. *Eur Rev Med Pharmacol Sci* 18, 3359–3354.

476. Pahila J, Ishikawa Y & Ohshima T (2019) Effects of ergothioneine on copper(I)-mediated oxidative damage. *J Agric Food Chem* 67, 3491–3501.

477. Cheah IK, Tang R, Ye P, et al. (2016) Liver ergothioneine accumulation in a guinea pig model of non-alcoholic fatty liver disease. A possible mechanism of defence? *Free Radic Res* 50, 14–25.

478. Sansbury BE, DeMartino AM, Xie Z, et al. (2014) Metabolomic analysis of pressure-overloaded and infarcted mouse hearts. *Circ Heart Fail* 7, 634–642.

479. Agudo-Barriuso M, Lázaro R, Nadal-Nicolás M, et al. (2013) Metabolomic changes in the rat retina after optic nerve crush. *Invest Ophthalmo* 56, 4249–4259.
479. Colognato R, Laurenza I, Fontana I, et al. (2006) Modulation of hydrogen peroxide-induced DNA damage, MAPKs activation and cell death in PC12 by ergothioneine. *Clin Nutr* **25**, 135–145.

480. Song TY, Chen CL, Liao JW, et al. (2010) Ergothioneine protects against neuronal injury induced by cisplatin both in vitro and in vivo. *Food Chem Toxicol* **48**, 3492–3499.

481. Nishida K, Takeuchi K, Hosoda A, et al. (2018) Ergothioneine ameliorates oxalipatin-induced peripheral neuropathy in rats. *Life Sci* **207**, 516–524.

482. D’Onofrio N, Servillo L, Giovane A, et al. (2016) Ergothioneine oxidation in the protection against high-glucose induced endothelial senescence: involvement of SIRT1 and SIRT6. *Free Radic Biol Med* **96**, 211–222.

483. Gunawardena D, Bennett L, Shanmugam K, et al. (2011) Antioxidant therapy in acute central nervous system injury: long-term benefits. *Antioxidants & Redox Signaling* **14**, 293–312.

484. Kell DB & Pretorius E (2015) On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. *Integr Biol* **7**, 1339–1377.

485. Goodman M, Bostick RM, Kucuk O, et al. (2011) Clinical trials of antioxidants as cancer prevention agents: past, present, and future. *Free Radic Biol Med* **51**, 1068–1084.

486. Arduini A, Eddy L & Hochstein P (1990) The reduction of ferryl myoglobin by ergothioneine: a novel function for ergothioneine. *Arch Biochem Biophys* **281**, 41–43.

487. Zimring JC, Smith N, Stowell SR, et al. (2014) Strain-specific red blood cell storage, metabolism, and eicosanoid generation in a mouse model. *Transfusion* **54**, 137–148.

488. Kell DB & Pretorius E (2015) On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. *Integr Biol* **7**, 1339–1377.

489. Badía MC, Mora NJ, et al. (2019) The effectiveness of vitamin E treatment in Alzheimer’s disease. *Int J Mol Sci* **20**, E879.

490. Smith E, Ottosson F, Hellstrand S, et al. (2009) Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental. *J Alzheimers Dis* **17**, 143–149.

491. Poston L, Briley AL, Seed PT, et al. (2006) Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. *Lancet* **367**, 1145–1154.

492. Oldham KM & Bowen PE (1998) Oxidative stress in critical care: is antioxidant supplementation beneficial? *J Am Diet Assoc* **98**, 1001–1008.

493. Rehman A, Collis CS, Yang M, et al. (1998) The effects of iron and vitamin C co-supplementation on oxidative damage to DNA in healthy volunteers. *Biochim Biophys Acta* **1364**, 293–298.

494. Cuzzocrea S, Riley DP, Caputi AP, et al. (2001) Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. *Pharmacol Rev* **53**, 135–159.

495. Gilgum-Sherki Y, Rosenbaum Z, Melamed E, et al. (2002) Antioxidant therapy in acute central nervous system injury: current state. *Pharmacol Rev* **54**, 271–284.

496. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* **142**, 37–46.

497. Valzir ND & Rodríguez-Iturbe B (2006) Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. *Nat Clin Pract Nephrol* **2**, 582–593.

498. Rodrigo R, Guichard C & Charles R (2007) Clinical pharmacology and therapeutic use of antioxidant vitamins. *Fund Clin Pharmacol* **21**, 111–127.

499. Bjelakovic G, Nikolova D, Glud LL, et al. (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. *JAMA* **297**, 842–857.

500. Bjelakovic G, Nikolova D, Glud LL, et al. (2008) Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane Database Syst Rev*, issue 2, CD007176.

501. Mendes-da-Silva RF, Lopes-de-Morais AA, Bandim-da-Silva ME, et al. (2014) Prooxidant versus antioxidant brain action of ascorbic acid in well-nourished and malnourished rats as a function of dose: a cortical spreading depression and malondialdehyde analysis. *Neuropharmacology* **86**, 155–160.

502. Zhang P & Omaye ST (2001) Antioxidant and prooxidant roles for β-carotene, α-tocopherol and ascorbic acid in human lung cells. *Toxicol In Vitro* **15**, 13–24.

503. Ullah MF, Khan HY, Zubair H, et al. (2011) The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer. *Cancer Chemother Pharmacol* **67**, 103–110.

504. Repine JE & Elkins ND (2012) Effect of ergothioneine on acute lung injury and inflammation in cytotoxic insufflated rats. *Prev Med* **54**, Suppl., S79–S82.

505. Martin KR (2010) The bioactive agent ergothioneine, a key component of dietary mushrooms, inhibits monocyte binding to endothelial cells characteristic of early cardiovascular disease. *J Med Food* **13**, 1340–1346.

506. Servillo L, D’Onofrio N & Balestrieri ML (2017) Ergothioneine antioxidant function: from chemistry to cardiovascular therapeutic potential. *J Cardiovasc Pharmacol* **69**, 183–191.

507. Darghouth D, Kochl B, Heider JF, et al. (2011) Alterations of red blood cell metabolome in overhydrated hereditary stoma-tocytosis. *Hematologica* **96**, 1861–1865.

508. Smith E, Ottosson F, Hellstrand S, et al. (2019) Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease. *Heart* **2019**, heartjnl-2019-315485 (epublication ahead of print version 31 October 2019).

509. Nurk E, Refsum H, Drevon CA, et al. (2010) Cognitive performance among the elderly in relation to the intake of plant products. *The Hordaland Health Study. Br J Nutr* **104**, 1190–1201.

510. Zhang S, Tomata Y, Sugiyama K, et al. (2017) Mushroom consumption and incident dementia in elderly Japanese: the J-Renal Cohort Study. *J Alzheimers Dis* **50**, 689–696.

511. Thangthaeng N, Miller MG, Gomes SM, et al. (2015) Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats. *Transfusion* **55**, 1190–1196.

512. Phan CW, David P & Sitaratnam V (2017) Edible and medicinal mushrooms: emerging brain food for the mitigation of neurodegenerative diseases. *J Med Food* **20**, 1–10.

513. Zhang S, Tomata Y, Sugiyama K, et al. (2017) Mushroom consumption and incident dementia in elderly Japanese: the J-Renal Cohort Study. *J Alzheimers Dis* **50**, 689–696.

514. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* **142**, 37–46.

515. Hatano T, Saiki S, Okuzumi A, et al. (2016) Identification of novel biomarkers for Parkinson’s disease by metabolomic technologies. *J Neurol Neurosurg Psychiatry* **87**, 295–301.
536. Muszyńska B & Sulkowska-Ziaka K (2015) Impact of food processing on non-hallucinogenic indole derivatives in edible mushrooms. In Processing and Impact on Active Components in Food, pp. 55–62 [V Preedy, editor]. San Diego, CA: Academic Press.

537. Cremades O, Díaz-Herrero MM, Carbonero-Aguilar P, et al. (2015) White button mushroom ergothioneine in aqueous extracts obtained by the application of enzymes and membrane technology. Food Biosci 10, 42–47.

538. Sánchez C (2017) Reactive oxygen species and antioxidant properties from mushrooms. Symb Syst Biotechnol 2, 13–22.

539. Duy Bao HN & Ohshima T (2013) Strategies to minimize oxidative deterioration in aquatic food products: application of natural antioxidants from edible mushrooms. In Lipid Oxidation, pp. 345–380 [U Nienaber and X Pan, editors]. Urbana, IL: AOCS Press.

540. Pérez-Sánchez A, Barrajón-Catalán E, Herranz-López M, et al. (2018) Nutraceuticals for skin care: a comprehensive review of human clinical studies. Nutrients 10, E403.

541. Lee CM (2016) Fifty years of research and development of cosmeceuticals: a contemporary review. J Cosmet Dermatol 15, 527–539.

542. Epstein H (2009) Cosmeceuticals and polyphenols. Clin Dermatol 27, 475–478.

543. Taofiq O, González-Paramás AM, Martins A, et al. (2016) Mushrooms: extracts and compounds in cosmetics, cosmeceuticals and nutricosmetics – a review. Industrial Crops Products 90, 38–48.

544. Wu Y, Choi M-H, Li J, et al. (2016) Mushroom cosmetics: the present and future. Cosmetics 3, 22.

545. Linder J (2012) Cosmeceutical treatment of the aging face. In Aesthetic Medicine, pp. 69–84 [PM Prendergast and MA Shiffman, editors]. Berlin: Springer.

546. Cronin H, Draelos ZD (2010) Top 10 botanical ingredients in 2010 anti-aging creams. J Cosmet Dermatol 9, 218–225.

547. Souyoul SA, Saussy KP & Lupo MP (2018) Nutraceuticals: a contemporary review. J Cosmet Dermatol 17, 5–16.

548. Norins AL (1962) Free radical formation in the skin following exposure to ultraviolet light. J Invest Dermatol 39, 445–448.

549. Hsue YC, Lo HW, Korivi M, et al. (2015) Dermato-protective properties of ergothioneine through induction of Nrf2/ARE-mediated antioxidant genes in UVA-irradiated human keratinocytes. Free Radic Biol Med 86, 102–117.

550. Botta C, Di Giorgio C, Sabatier AS, et al. (2008) Genotoxicity of visible light (400–800 nm) and photoprotection assessment of ectoin, 3-ergothioneine and mannitol and four sunscreens. J Photochem Photobiol B 91, 24–34.

551. Bazela K, Solyga-Zurek A, Debowska R, et al. (2014) 3-Ergothioneine protects skin cells against UV-induced damage – a preliminary study. Cosmetics 1, 51–60.

552. Sao Emani C, Williams MJ, Van Helden PD, et al. (2018) γ-Glutamylcysteine protects ergothioneine-deficient Mycobacterium tuberculosis mutants against oxidative and nitrosative stress. Biochem Biophys Res Commun 495, 174–178.

553. Sao Emani C, Williams MJ, Van Helden PD, et al. (2018) Generation and characterization of thiol-deficient Mycobacterium tuberculosis mutants. Sci Data 5, 180184.

554. Jothivasan VK & Hamilton CJ (2008) Mycothiol: synthesis, biosynthesis and biological functions of the major low molecular weight thiol in actinomycetes. Nat Prod Rep 25, 1091–1117.

555. Feng J, Che Y, Mile J, et al. (2006) The gene nclg2918 encodes a novel maleylpyruvate isomerase that needs mycothiol as cofactor and links mycothiol biosynthesis and genisine
assimilation in *Corynebacterium glutamicum*. *J Biol Chem* **281**, 10778–10785.

556. Newton GL, Buchmeier N & Fahey RC (2008) Biosynthesis and functions of mycothiol, the unique protective thiol of Actinobacteria. *Microbiol Mol Biol Rev* **72**, 471–494.

557. Bzymek KP, Newton GL, Ta P, et al. (2007) Mycothiol import by *Mycobacterium smegmatis* and function as a resource for metabolic precursors and energy production. *J Bacteriol* **189**, 6796–6805.

558. Brummel MC (1985) In search of a physiological function for l-ergothioneine. *Mod Hypotheses* **18**, 351–370.

559. Brummel MC (1989) In search of a physiological function for l-ergothioneine – II. *Mod Hypotheses* **30**, 39–48.

560. Wang M, Zhao Q & Liu W (2015) The versatile low-molecular-weight thiols: beyond cell protection. *Bioessays* **37**, 1262–1267.

561. Zhao Q, Wang M, Xu D, et al. (2015) Metabolic coupling of two small-molecule thiols programs the biosynthesis of lincomycin A. *Nature* **518**, 115–119.

562. Goldberg A (1959) The enzymatic formation of haem by the incorporation of iron into protoporphyrin; importance of ascorbic acid, ergothioneine and glutathione. *Br J Haematol* **5**, 150–157.

563. Anonymous (2019) Clinical trials with mushrooms. https://clinicaltrials.gov/ct2/show/NCT03641404 (accessed January 2020).

564. Cheah IK (2018) Investigating the efficacy of ergothioneine to delay cognitive decline. https://clinicaltrials.gov/ct2/show/NCT03641404 (accessed August 2019).

565. Gamage AM, Liao C, Cheah IK, et al. (2018) The proteobacterial species *Burkholderia pseudomallei* produces ergothioneine, which enhances virulence in mammalian infection. *FASEB J* **2018**, f201800716.

566. Heath H & Wildy J (1956) Biosynthesis of ergothioneine and histidine by claviceps-purpurea. 1. Incorporation of [2-14C] acetate. *Biochem J* **64**, 612–620.

567. Heath H & Wildy J (1957) Biosynthesis of ergothioneine. *Nature* **179**, 196–197.

568. Pan L, Yu J, Ren D, et al. (2019) Metabolic analysis of ergothioneine synthesis in *Lactobacillus casei* Zhang during growth to generation 4,000 under conditions of glucose restriction. *J Dairy Sci* **102**, 3851–3867.

569. Pluskal T, Nakamura T, Villar-Briones A, et al. (2010) Metabolic profiling of the fission yeast *S. pombe*: quantification of compounds under different temperatures and genetic perturbation. *Mol Biosyst* **6**, 182–198.

570. van der Hoek SA, Darbani B, Zugaj K, et al. (2019) Engineering the yeast *Saccharomyces cerevisiae* for the production of l- (+)-ergothioneine. *BioRxiv*, 2019, 667592.

571. Soglia S, Zinelu A, Mangoni AA, et al. (2014) Clinical and biochemical correlates of serum l-ergothioneine concentrations in community-dwelling middle-aged and older adults. *PLOS ONE* **9**, e84918.

572. Nishigori H, Hayashi R, Lee JW, et al. (1984) Effect of MPG on glaucocorticoid-induced cataract formation in developing chick embryo. *Invest Ophthalmol Vis Sci* **25**, 1051–1055.

573. Song TY, Yang NC, Chen CL, et al. (2017) Protective effects and possible mechanisms of ergothioneine and hspidin against methylglyoxal-induced injuries in rat pheochromocytoma cells. *Oxid Med Cell Longev* **2017**, 4824371.

574. Guijarro MV, Indart A, Aruoma OF, et al. (2002) Effects of ergothioneine on diabetic embryopathy in pregnant rats. *Food Chem Toxicol* **40**, 1751–1755.

575. Oztürkler Y, Yıldız S, Gińgor O, et al. (2010) The effects of l-ergothioneine and l-ascorbic acid on the *in vitro* maturation (IVM) and embryonic development (IVC) of sheep oocytes. *Kafkas Universitesi Veteriner Fakultesi Dergisi* **16**, 757–763.

576. Zullo G, Albero G, Neglia G, et al. (2016) l-Ergothioneine supplementation during culture improves quality of bovine in *vitro*-produced embryos. *Theriogenology* **85**, 688–697.

577. Moncaster JA, Walsh DT, Gentleman SM, et al. (2002) Ergothioneine treatment protects neurons against N-methyl-D-aspartate excitotoxicity in an *in vivo* rat retinal model. *Neurosci Lett* **328**, 55–59.

578. Kawano H, Higuchi F, Mayumi T, et al. (1982) Studies on ergothioneine. VII. Some effects on ergothioneine on glycolytic metabolism in red blood cells from rats. *Chem Pharm Bull (Tokyo)* **30**, 2611–2613.

579. Kimura C, Nakuma I, Igarashi K, et al. (2005) β-Hydroxyergothioneine, a new ergothioneine derivative from the mushroom *Lypphylum connatum*, and its protective activity against carbon tetrachloride-induced injury in primary culture hepatocytes. *Biosci Biotechnol Biochem* **69**, 357–363.

580. Yoshida S, Shime H, Funami K, et al. (2017) The anti-oxidant ergothioneine augments the immunomodulatory function of TLR agonists by direct action on macrophages. *PLOS ONE* **12**, e0169360.

581. Yoshida S, Shime H, Matsumoto M, et al. (2019) Anti-oxidative amino acid l-ergothioneine modulates the tumor microenvironment to facilitate adjuvant vaccine immunotherapy. *Front Immunol* **10**, 671.

582. Shinozaki Y, Furuchi K, Toyama T, et al. (2017) Impaired maturation of the carmine/organic cation transporter l-ergothioneine axis is mediated by intestinal transporter dysfunction in chronic kidney disease. *Kidney Int* **92**, 1356–1369.

583. Menna P, Salvatorelli E, Giampietro R, et al. (2002) Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines. *Chem Res Toxicol* **15**, 1179–1189.

584. Song TY, Lin HC, Chen CL, et al. (2014) Ergothioneine and melatonin attenuate oxidative stress and protect against learning and memory deficits in C57BL/6j mice treated with γ-galactoside. *Free Radic Res* **48**, 1049–1060.

585. Motokashi N, Mori I, Sugira Y, et al. (1974) Metal complexes of ergothioneine. *Chem Pharmaceut Bull* **22**, 654–657.

586. Motokashi N, Mori I & Sugira Y (1976) Complexing of copper-ion by ergothioneine. *Chem Pharmaceut Bull* **24**, 2364–2368.

587. Rabenstein DL & Isab AA (1982) A proton nuclear magnetic resonance study of the interaction of mercury with intact human erythrocytes. *Biochim Biophys Acta* **721**, 374–384.

588. Hartman PE & Citardi MJ (1986) Protection afforded by carnosine and by ergothioneine against bacteriophage-P22 inactivation by gamma-irradiation. *Environ Mol Mutagen* **8**, 35–35.

589. Hartman Z, Hartman PE & Owens RA (1986) Ergothioneine (2–hydroxyergothioneine, a new ergothioneine derivative –) as an antimutagen in vitro. *Environ Mol Mutagen* **8**, 36–36.

590. Hartman Z & Hartman PE (1987) Interception of some direct-acting mutagens formed from nitrosation of spermidine and spermine by ergothioneine acting mutagens by ergothioneine. *Environ Mol Mutagen* **11**, 15–17.

591. Hartman PE, Hartman Z & Citardi MJ (1988) Ergothioneine, histidine, and two naturally occurring histidine dipeptides as radioprotectors against γ-irradiation inactivation of bacteriophages T4 and P22. *Radiat Res* **114**, 319–330.

592. Ishimoto T, Nakamichi N, Hosotani H, et al. (2014) Organic cation transporter-mediated ergothioneine uptake in mouse neural progenitor cells suppresses proliferation and promotes differentiation into neurons. *PLOS ONE* **9**, e89434.

593. Misiti F, Castagnola M, Zuppi C, et al. (2001) Role of ergothioneine on S-nitrosoglutathione catabolism. *Biochem J* **356**, 799–804.
594. Ishimoto T, Masuo Y, Kato Y, et al. (2019) Ergothioneine-induced neuronal differentiation is mediated through activation of S6K1 and neurotrophin 4/5-TrkB signaling in murine neural stem cells. *Cell Signal* **53**, 269–280.

595. Chaves NA, Alegria TGP, Dantas IS, et al. (2019) Impaired antioxidant capacity causes a disruption of metabolic homeostasis in sickle erythrocytes. *Free Radic Biol Med* **141**, 34–46.

596. Mann T & Leone E (1953) Studies on the metabolism of semen. 8. Ergothioneine as a normal constituent of boar seminal plasma. Purification and crystallization. Site of formation and function. *Biochem J* **53**, 140–148.

597. Williamson RD, McCarthy FP, Manna S, et al. (2020) l(-)-Ergothioneine significantly improves the clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model. *Hypertension* **75**, 561–568.